{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T11:18:05Z","timestamp":1794395885474,"version":"4.9.0"},"reference-count":297,"publisher":"Bentham Science Publishers Ltd.","issue":"28","funder":[{"DOI":"10.13039\/501100005230","name":"Natural Science Foundation of Chongqing, China","doi-asserted-by":"publisher","award":["cstc2019jcyj-zdxmX0021"],"award-info":[{"award-number":["cstc2019jcyj-zdxmX0021"]}],"id":[{"id":"10.13039\/501100005230","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22071012"],"award-info":[{"award-number":["22071012"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Staphylococcus aureus is a leading cause of septicemia, endocarditis, pneumonia, skin and soft tissue infections, bone and joint infections, and hospital-acquired infections. In particular, methicillin-resistant Staphylococcus aureus (MRSA) is associated\nwith high morbidity and mortality, and continues to be a major public health problem.\nThe emergence of multidrug-resistant MRSA strains along with the wide consumption\nof antibiotics has made anti-MRSA treatment a huge challenge. Novel treatment strategies (e.g., novel antimicrobials and new administrations) against MRSA are urgently\nneeded. In the past decade, pharmaceutical companies have invested more in the research and development (R&amp;D) of new antimicrobials and strategies, spurred by favorable policies. All research articles were collected from authentic online databases, including Google Scholar, PubMed, Scopus, and Web of Science, by using different combinations of keywords, including \u2018anti-MRSA\u2019, \u2018antibiotic\u2019, \u2018antimicrobial\u2019, \u2018clinical trial\u2019,\n\u2018clinical phase\u2019, clinical studies\u2019, and \u2018pipeline\u2019. The information extracted from articles\nwas compared to information provided on the drug manufacturer\u2019s website and ClinicalTrials.gov (https:\/\/clinicaltrials.gov\/) to confirm the latest development phase of anti-MRSA agents. The present review focuses on the current development status of new\nanti-MRSA strategies concerning chemistry, pharmacological target(s), indications,\nroute of administration, efficacy and safety, pharmacokinetics, and pharmacodynamics,\nand aims to discuss the challenges and opportunities in developing drugs for anti-MRSA\ninfections.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0109298673249381231130111352","type":"journal-article","created":{"date-parts":[[2024,2,4]],"date-time":"2024-02-04T10:10:36Z","timestamp":1707041436000},"page":"4425-4460","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Treatment of MRSA Infection: Where are We?"],"prefix":"10.2174","volume":"31","author":[{"given":"Adila","family":"Nazli","sequence":"first","affiliation":[{"name":"Chongqing Key Laboratory of Natural Product Synthesis and Drug Research, School of Pharmaceutical\nSciences, Chongqing University, Chongqing, 401331, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlan","family":"Tao","sequence":"additional","affiliation":[{"name":"Chongqing School, University of Chinese\nAcademy of Sciences (UCAS Chongqing), Chongqing, 400714, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengyao","family":"You","sequence":"additional","affiliation":[{"name":"Chongqing Key Laboratory of Natural Product Synthesis and Drug Research, School of Pharmaceutical\nSciences, Chongqing University, Chongqing, 401331, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"He","sequence":"additional","affiliation":[{"name":"Chongqing School, University of Chinese\nAcademy of Sciences (UCAS Chongqing), Chongqing, 400714, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"He","sequence":"additional","affiliation":[{"name":"Chongqing Key Laboratory of Natural Product Synthesis and Drug Research, School of Pharmaceutical\nSciences, Chongqing University, Chongqing, 401331, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"654038","DOI":"10.3389\/fmolb.2021.654038","volume":"8","author":"Walsh L.","year":"2021","unstructured":"Walsh L.; Johnson C.N.; Hill C.; Ross R.P.; Efficacy of phage- and bacteriocin-based therapies in combatting nosocomial MRSA infections. Front Mol Biosci  2021,8(4),654038","journal-title":"Front Mol Biosci"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1001\/jama.299.10.1190","volume":"299","author":"Diekema D.J.","year":"2008","unstructured":"Diekema D.J.; Climo M.; Preventing MRSA infections. JAMA  2008,299(10),1190-1192","journal-title":"JAMA"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13059-017-1252-9","volume":"18","author":"Harkins C.P.","year":"2017","unstructured":"Harkins C.P.; Pichon B.; Doumith M.; Parkhill J.; Westh H.; Tomasz A.; de Lencastre H.; Bentley S.D.; Kearns A.M.; Holden M.T.G.; Methicillin-resistant Staphylococcus aureus emerged long before the introduction of methicillin into clinical practice. Genome Biol  2017,18(1),130-141","journal-title":"Genome Biol"},{"key":"ref=4","first-page":"223","volume":"83","author":"Morell E.A.","year":"2010","unstructured":"Morell E.A.; Balkin D.M.; Methicillin-resistant Staphylococcus aureus: A pervasive pathogen highlights the need for new antimicrobial development. Yale J Biol Med  2010,83(4),223-233","journal-title":"Yale J Biol Med"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/sj.eye.6701465","volume":"19","author":"Shanmuganathan V.A.","year":"2005","unstructured":"Shanmuganathan V.A.; Armstrong M.; Buller A.; Tullo A.B.; External ocular infections due to methicillin-resistant Staphylococcus aureus (MRSA). Eye (Lond)  2005,19(3),284-291","journal-title":"Eye (Lond)"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"9212","DOI":"10.1021\/ja8029448","volume":"130","author":"Villegas-Estrada A.","year":"2008","unstructured":"Villegas-Estrada A.; Lee M.; Hesek D.; Vakulenko S.B.; Mobashery S.; Co-opting the cell wall in fighting methicillin-resistant Staphylococcus aureus: Potent inhibition of PBP 2a by two anti-MRSA \u03b2-lactam antibiotics. J Am Chem Soc  2008,130(29),9212-9213","journal-title":"J Am Chem Soc"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"513","DOI":"10.5144\/0256-4947.2012.513","volume":"32","author":"El Amin N.M.","year":"2012","unstructured":"El Amin N.M.; Faidah H.S.; Methicillin-resistant Staphylococcus aureus in the Western region of Saudi Arabia: Prevalence and antibiotic susceptibility pattern. Ann Saudi Med  2012,32(5),513-516","journal-title":"Ann Saudi Med"},{"key":"ref=8","first-page":"742","volume":"130","author":"Chatterjee S.S.","year":"2009","unstructured":"Chatterjee S.S.; Ray P.; Aggarwal A.; Das A.; Sharma M.; A community-based study on nasal carriage of Staphylococcus aureus. Indian J Med Res  2009,130(6),742-748","journal-title":"Indian J Med Res"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.ijantimicag.2011.09.030","volume":"39","author":"Stefani S.","year":"2012","unstructured":"Stefani S.; Chung D.R.; Lindsay J.A.; Friedrich A.W.; Kearns A.M.; Westh H.; MacKenzie F.M.; Meticillin-resistant Staphylococcus aureus (MRSA): Global epidemiology and harmonisation of typing methods. Int J Antimicrob Agents  2012,39(4),273-282","journal-title":"Int J Antimicrob Agents"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJM200101043440102","volume":"344","author":"von Eiff C.","year":"2001","unstructured":"von Eiff C.; Becker K.; Machka K.; Stammer H.; Peters G.; Nasal carriage as a source of Staphylococcus aureus bacteremia. N Engl J Med  2001,344(1),11-16","journal-title":"N Engl J Med"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1128\/JCM.02423-12","volume":"51","author":"Clarridge J.E.","year":"2013","unstructured":"Clarridge J.E.; Harrington A.T.; Roberts M.C.; Soge O.O.; Maquelin K.; Impact of strain typing methods on assessment of relationship between paired nares and wound isolates of methicillin-resistant Staphylococcus aureus. J Clin Microbiol  2013,51(1),224-231","journal-title":"J Clin Microbiol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"e00020-18","DOI":"10.1128\/CMR.00020-18","volume":"31","author":"Lakhundi S.","year":"2018","unstructured":"Lakhundi S.; Zhang K.; Methicillin-resistant Staphylococcus aureus: Molecular characterization, evolution, and epidemiology. Clin Microbiol Rev  2018,31(4),e00020-18","journal-title":"Clin Microbiol Rev"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"e92760","DOI":"10.1371\/journal.pone.0092760","volume":"9","author":"David M.Z.","year":"2014","unstructured":"David M.Z.; Cadilla A.; Boyle-Vavra S.; Daum R.S.; Replacement of HA-MRSA by CA-MRSA infections at an academic medical center in the midwestern United States, 2004-5 to 2008. PLoS One  2014,9(4),e92760","journal-title":"PLoS One"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"041001","DOI":"10.1088\/1752-7155\/8\/4\/041001","volume":"8","author":"Bean H.D.","year":"2014","unstructured":"Bean H.D.; Zhu J.; Sengle J.C.; Hill J.E.; Identifying methicillin-resistant Staphylococcus aureus (MRSA) lung infections in mice via breath analysis using secondary electrospray ionization-mass spectrometry (SESI-MS). J Breath Res  2014,8(4),041001-41001","journal-title":"J Breath Res"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3201\/eid0702.010237","volume":"7","author":"Tenover F.","year":"2001","unstructured":"Tenover F.; Biddle J.W.; Lancaster M.V.; Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Infect Dis  2001,7(2),327-332","journal-title":"Emerg Infect Dis"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"76","DOI":"10.4103\/jms.jms_25_17","volume":"32","author":"Shrivastava S.","year":"2018","unstructured":"Shrivastava S.; Shrivastava P.; Ramasamy J.; World health organization releases global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. J Med Society  2018,32(1),76-77","journal-title":"J Med Society"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1080\/13543784.2020.1750595","volume":"29","author":"Bassetti M.","year":"2020","unstructured":"Bassetti M.; Del Puente F.; Magnasco L.; Giacobbe D.R.; Innovative therapies for acute bacterial skin and skin-structure infections (ABSSSI) caused by methicillin-resistant Staphylococcus aureus : Advances in phase I and II trials. Expert Opin Investig Drugs  2020,29(5),495-506","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1093\/jac\/dkl393","volume":"58","author":"French G.L.","year":"2006","unstructured":"French G.L.; Bactericidal agents in the treatment of MRSA infections--the potential role of daptomycin. J Antimicrob Chemother  2006,58(6),1107-1117","journal-title":"J Antimicrob Chemother"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1001\/jama.298.15.1826","volume":"298","author":"Zeller J.L.","year":"2007","unstructured":"Zeller J.L.; Burke A.E.; Glass R.M.; MRSA Infections. JAMA  2007,298(15),1826-1826","journal-title":"JAMA"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S0195-6701(03)00147-6","volume":"54","author":"Wilcox M.H.","year":"2003","unstructured":"Wilcox M.H.; Hall J.; Pike H.; Templeton P.A.; Fawley W.N.; Parnell P.; Verity P.; Use of perioperative mupirocin to prevent methicillin-resistant Staphylococcus aureus (MRSA) orthopaedic surgical site infections. J Hosp Infect  2003,54(3),196-201","journal-title":"J Hosp Infect"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.ijantimicag.2008.05.007","volume":"32","author":"Hsu D.I.","year":"2008","unstructured":"Hsu D.I.; Hidayat L.K.; Quist R.; Hindler J.; Karlsson A.; Yusof A.; Wong-Beringer A.; Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections. Int J Antimicrob Agents  2008,32(5),378-385","journal-title":"Int J Antimicrob Agents"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1517\/17460441.2013.807246","volume":"8","author":"Kurosu M.","year":"2013","unstructured":"Kurosu M.; Siricilla S.; Mitachi K.; Advances in MRSA drug discovery: Where are we and where do we need to be? Expert Opin Drug Discov  2013,8(9),1095-1116","journal-title":"Expert Opin Drug Discov"},{"key":"ref=23","first-page":"879","volume":"9","author":"Weis F.","year":"2008","unstructured":"Weis F.; Beiras-Fernandez A.; Schelling G.; Daptomycin, a lipopeptide antibiotic in clinical practice. Curr Opin Investig Drugs  2008,9(8),879-884","journal-title":"Curr Opin Investig Drugs"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1592\/phco.24.1.41.34802","volume":"24","author":"Tedesco K.L.","year":"2004","unstructured":"Tedesco K.L.; Rybak M.J.; Daptomycin. Pharmacotherapy  2004,24(1),41-57","journal-title":"Pharmacotherapy"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jinf.2007.05.180","volume":"55","author":"Enoch D.A.","year":"2007","unstructured":"Enoch D.A.; Bygott J.M.; Daly M.L.; Karas J.A.; Daptomycin. J Infect  2007,55(3),205-213","journal-title":"J Infect"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1086\/504084","volume":"42","author":"Patel J.B.","year":"2006","unstructured":"Patel J.B.; Jevitt L.A.; Hageman J.; McDonald L.C.; Tenover F.C.; An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus. Clin Infect Dis  2006,42(11),1652-1653","journal-title":"Clin Infect Dis"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"553","DOI":"10.2174\/1389200216666151001121004","volume":"16","author":"Kishor K.","year":"2015","unstructured":"Kishor K.; Dhasmana N.; Kamble S.; Sahu R.; Linezolid induced adverse drug reactions-an update. Curr Drug Metab  2015,16(7),553-559","journal-title":"Curr Drug Metab"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1185\/03007990903512057","volume":"26","author":"Stein G.E.","year":"2010","unstructured":"Stein G.E.; Wells E.M.; The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus : Vancomycin and linezolid. Curr Med Res Opin  2010,26(3),571-588","journal-title":"Curr Med Res Opin"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1080\/08998280.2006.11928154","volume":"19","author":"Greer N.D.","year":"2006","unstructured":"Greer N.D.; Tigecycline (Tygacil): The first in the glycylcycline class of antibiotics. Proc Bayl Univ Med Cent  2006,19(2),155-161","journal-title":"Proc Bayl Univ Med Cent"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"714","DOI":"10.3122\/jabfm.2010.06.090270","volume":"23","author":"Frei C.R.","year":"2010","unstructured":"Frei C.R.; Miller M.L.; Lewis J.S.; Lawson K.A.; Hunter J.M.; Oramasionwu C.U.; Talbert R.L.; Trimethoprim-sulfamethoxazole or clindamycin for community-associated MRSA (CA-MRSA) skin infections. J Am Board Fam Med  2010,23(6),714-719","journal-title":"J Am Board Fam Med"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1086\/525536","volume":"46","author":"Goldstein E.J.C.","year":"2008","unstructured":"Goldstein E.J.C.; Proctor R.A.; Role of folate antagonists in the treatment of methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis  2008,46(4),584-593","journal-title":"Clin Infect Dis"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"S191","DOI":"10.1086\/519470","volume":"45","author":"Kollef M.H.","year":"2007","unstructured":"Kollef M.H.; Limitations of vancomycin in the management of resistant staphylococcal infections. Clin Infect Dis  2007,45(3)(Suppl. 3),S191-S195","journal-title":"Clin Infect Dis"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1080\/14740338.2019.1621288","volume":"18","author":"Bassetti M.","year":"2019","unstructured":"Bassetti M.; Peghin M.; Castaldo N.; Giacobbe D.R.; The safety of treatment options for acute bacterial skin and skin structure infections. Expert Opin Drug Saf  2019,18(8),635-650","journal-title":"Expert Opin Drug Saf"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1089\/107662903322762833","volume":"9","author":"Jevitt L.A.","year":"2003","unstructured":"Jevitt L.A.; Smith A.J.; Williams P.P.; Raney P.M.; McGowan J.E.; Tenover F.C.; In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium. Microb Drug Resist  2003,9(4),389-393","journal-title":"Microb Drug Resist"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1128\/AAC.50.4.1581-1585.2006","volume":"50","author":"Sakoulas G.","year":"2006","unstructured":"Sakoulas G.; Alder J.; Thauvin-Eliopoulos C.; Moellering R.C.; Eliopoulos G.M.; Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother  2006,50(4),1581-1585","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1086\/420818","volume":"38","author":"Arbeit R.D.","year":"2004","unstructured":"Arbeit R.D.; Maki D.; Tally F.P.; Campanaro E.; Eisenstein B.I.; The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis  2004,38(12),1673-1681","journal-title":"Clin Infect Dis"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s10156-012-0501-9","volume":"19","author":"Aikawa N.","year":"2013","unstructured":"Aikawa N.; Kusachi S.; Mikamo H.; Takesue Y.; Watanabe S.; Tanaka Y.; Morita A.; Tsumori K.; Kato Y.; Yoshinari T.; Efficacy and safety of intravenous daptomycin in Japanese patients with skin and soft tissue infections. J Infect Chemother  2013,19(3),447-455","journal-title":"J Infect Chemother"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"353","DOI":"10.4088\/PCC.09r00853","volume":"11","author":"Quinn D.K.","year":"2009","unstructured":"Quinn D.K.; Stern T.A.; Linezolid and serotonin syndrome. Prim Care Companion J Clin Psychiatry  2009,11(6),353-356","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1177\/0091270007300263","volume":"47","author":"Van Wart S.A.","year":"2007","unstructured":"Van Wart S.A.; Cirincione B.B.; Ludwig E.A.; Meagher A.K.; Korth-Bradley J.M.; Owen J.S.; Population pharmacokinetics of tigecycline in healthy volunteers. J Clin Pharmacol  2007,47(6),727-737","journal-title":"J Clin Pharmacol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S1068-607X(02)00113-0","volume":"9","author":"Murchison A.","year":"2002","unstructured":"Murchison A.; Quinupristin\u2013dalfopristin: A streptogramin antibiotic. Prim Care Update Ob Gyns  2002,9(5),176-177","journal-title":"Prim Care Update Ob Gyns"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1086\/367662","volume":"36","author":"Eliopoulos G.M.","year":"2003","unstructured":"Eliopoulos G.M.; Eliopoulos G.M.; Quinupristin-dalfopristin and linezolid: Evidence and opinion. Clin Infect Dis  2003,36(4),473-481","journal-title":"Clin Infect Dis"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"e0230383","DOI":"10.1371\/journal.pone.0230383","volume":"15","author":"Ma H.","year":"2020","unstructured":"Ma H.; Cheng J.; Peng L.; Gao Y.; Zhang G.; Luo Z.; Adjunctive rifampin for the treatment of Staphylococcus aureus bacteremia with deep infections: A meta-analysis. PLoS One  2020,15(3),e0230383","journal-title":"PLoS One"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"3575","DOI":"10.1093\/jac\/dkw333","volume":"71","author":"Dryden M.","year":"2016","unstructured":"Dryden M.; Zhang Y.; Wilson D.; Iaconis J.P.; Gonzalez J.; A Phase III, randomized, controlled, non-inferiority trial of ceftaroline fosamil 600 mg every 8 h versus vancomycin plus aztreonam in patients with complicated skin and soft tissue infection with systemic inflammatory response or underlying comorbidities. J Antimicrob Chemother  2016,71(12),3575-3584","journal-title":"J Antimicrob Chemother"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1086\/655827","volume":"51","author":"Corey G.R.","year":"2010","unstructured":"Corey G.R.; Wilcox M.; Talbot G.H.; Friedland H.D.; Baculik T.; Witherell G.W.; Critchley I.; Das A.F.; Thye D.; Integrated analysis of CANVAS 1 and 2: Phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis  2010,51(6),641-650","journal-title":"Clin Infect Dis"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.jaip.2016.03.008","volume":"4","author":"Blumenthal K.G.","year":"2016","unstructured":"Blumenthal K.G.; Kuhlen J.L.; Weil A.A.; Varughese C.A.; Kubiak D.W.; Banerji A.; Shenoy E.S.; Adverse drug reactions associated with ceftaroline use: A 2-center retrospective cohort. J Allergy Clin Immunol Pract  2016,4(4),740-746","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1155\/1998\/538090","volume":"9","author":"Smieja M.","year":"1998","unstructured":"Smieja M.; Current indications for the use of clindamycin: A critical review. Can J Infect Dis  1998,9(1),22-28","journal-title":"Can J Infect Dis"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1099\/jmm.0.45610-0","volume":"53","author":"Geric B.","year":"2004","unstructured":"Geric B.; Rupnik M.; Gerding D.N.; Grabnar M.; Johnson S.; Distribution of Clostridium difficile variant toxinotypes and strains with binary toxin genes among clinical isolates in an American hospital. J Med Microbiol  2004,53(9),887-894","journal-title":"J Med Microbiol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1056\/NEJMoa1403789","volume":"372","author":"Miller L.G.","year":"2015","unstructured":"Miller L.G.; Daum R.S.; Creech C.B.; Young D.; Downing M.D.; Eells S.J.; Pettibone S.; Hoagland R.J.; Chambers H.F.; Clindamycin versus trimethoprim-sulfamethoxazole for uncomplicated skin infections. N Engl J Med  2015,372(12),1093-1103","journal-title":"N Engl J Med"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"k341","DOI":"10.1136\/bmj.k341","volume":"360","author":"Crellin E.","year":"2018","unstructured":"Crellin E.; Mansfield K.E.; Leyrat C.; Nitsch D.; Douglas I.J.; Root A.; Williamson E.; Smeeth L.; Tomlinson L.A.; Trimethoprim use for urinary tract infection and risk of adverse outcomes in older patients: Cohort study. BMJ  2018,360,k341","journal-title":"BMJ"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1056\/NEJMoa1507476","volume":"374","author":"Talan D.A.","year":"2016","unstructured":"Talan D.A.; Mower W.R.; Krishnadasan A.; Abrahamian F.M.; Lovecchio F.; Karras D.J.; Steele M.T.; Rothman R.E.; Hoagland R.; Moran G.J.; Trimethoprim\u2013sulfamethoxazole versus placebo for uncomplicated skin abscess. N Engl J Med  2016,374(9),823-832","journal-title":"N Engl J Med"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1128\/AAC.03688-14","volume":"59","author":"Shorr A.F.","year":"2015","unstructured":"Shorr A.F.; Lodise T.P.; Corey G.R.; De Anda C.; Fang E.; Das A.F.; Prokocimer P.; Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections. Antimicrob Agents Chemother  2015,59(2),864-871","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0924-8579(98)00025-9","volume":"10","author":"Wilson A.P.R.","year":"1998","unstructured":"Wilson A.P.R.; Comparative safety of teicoplanin and vancomycin. Int J Antimicrob Agents  1998,10(2),143-152","journal-title":"Int J Antimicrob Agents"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","volume":"370","author":"Boucher H.W.","year":"2014","unstructured":"Boucher H.W.; Wilcox M.; Talbot G.H.; Puttagunta S.; Das A.F.; Dunne M.W.; Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med  2014,370(23),2169-2179","journal-title":"N Engl J Med"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.ijantimicag.2017.11.008","volume":"51","author":"Bouza E.","year":"2018","unstructured":"Bouza E.; Valerio M.; Soriano A.; Morata L.; Carus E.G.; Rodr\u00edguez-Gonz\u00e1lez C.; Hidalgo-Tenorio M.C.; Plata A.; Mu\u00f1oz P.; Vena A.; Alvarez-Uria A.; Fern\u00e1ndez-Cruz A.; Nieto A.A.; Artero A.; Allende J.M.B.; Morell E.B.; Candel-Gonz\u00e1lez F.J.; Castelo L.; Cobo J.; del Carmen G\u00e1lvez Contreras M.; Fern\u00e1ndez R.G.; Horcajada J.P.; Guisado-Vasco P.; Losa J.E.; Herv\u00e1s R.; Iftimie S.M.; Mej\u00edas M.E.J.; Jover F.; Ferreiro J.L.L.; Serrano A.B.L.; Malmierca E.; Masi\u00e1 M.; Sempere M.R.O.; Nieto A.R.; Rodriguez-Pardo D.; Alvarez S.J.R.; San Juan R.; Cepeda C.S.; Berrocal M.A.S.; Sobrino B.; Sorl\u00ed L.; Dalbavancin in the treatment of different gram-positive infections: A real-life experience. Int J Antimicrob Agents  2018,51(4),571-577","journal-title":"Int J Antimicrob Agents"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1086\/587896","volume":"46","author":"Stryjewski M.E.","year":"2008","unstructured":"Stryjewski M.E.; Graham D.R.; Wilson S.E.; O\u2019Riordan W.; Young D.; Lentnek A.; Ross D.P.; Fowler V.G.; Hopkins A.; Friedland H.D.; Barriere S.L.; Kitt M.M.; Corey G.R.; Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis  2008,46(11),1683-1693","journal-title":"Clin Infect Dis"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1086\/341026","volume":"35","author":"Graham D.R.","year":"2002","unstructured":"Graham D.R.; Talan D.A.; Nichols R.L.; Lucasti C.; Corrado M.; Morgan N.; Fowler C.L.; Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: A randomized, open-label trial. Clin Infect Dis  2002,35(4),381-389","journal-title":"Clin Infect Dis"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/j.1742-1241.1998.tb11567.x","volume":"52","author":"Nicodemo A.C.","year":"1998","unstructured":"Nicodemo A.C.; Robledo J.A.; Jasovich A.; Neto W.; A multicentre, double-blind, randomised study comparing the efficacy and safety of oral levofloxacin versus ciprofloxacin in the treatment of uncomplicated skin and skin structure infections. Int J Clin Pract  1998,52(2),69-74","journal-title":"Int J Clin Pract"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s15010-009-8468-x","volume":"37","author":"Vick-Fragoso R.","year":"2009","unstructured":"Vick-Fragoso R.; Hern\u00e1ndez-Oliva G.; Cruz-Alc\u00e1zar J.; Am\u00e1bile-Cuevas C.F.; Arvis P.; Reimnitz P.; Bogner J.R.; Group S.S.; Efficacy and safety of sequential intravenous\/oral moxifloxacin vs intravenous\/oral amoxicillin\/clavulanate for complicated skin and skin structure infections. Infection  2009,37(5),407-417","journal-title":"Infection"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/j.clinthera.2005.09.005","volume":"27","author":"Smith K.","year":"2005","unstructured":"Smith K.; Leyden J.J.; Safety of doxycycline and minocycline: A systematic review. Clin Ther  2005,27(9),1329-1342","journal-title":"Clin Ther"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1086\/380125","volume":"38","author":"Hershberger E.","year":"2004","unstructured":"Hershberger E.; Donabedian S.; Konstantinou K.; Zervos M.J.; Eliopoulos G.M.; Quinupristin-dalfopristin resistance in gram-positive bacteria: Mechanism of resistance and epidemiology. Clin Infect Dis  2004,38(1),92-98","journal-title":"Clin Infect Dis"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s10156-007-0521-Z","volume":"13","author":"Yamaoka T.","year":"2007","unstructured":"Yamaoka T.; The bactericidal effects of anti-MRSA agents with rifampicin and sulfamethoxazole-trimethoprim against intracellular phagocytized MRSA. J Infect Chemother  2007,13(3),141-146","journal-title":"J Infect Chemother"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"4478","DOI":"10.1128\/AAC.00194-12","volume":"56","author":"Saravolatz L.D.","year":"2012","unstructured":"Saravolatz L.D.; Pawlak J.; Johnson L.; Bonilla H.; Saravolatz L.D.; Fakih M.G.; Fugelli A.; Olsen W.M.; In vitro activities of LTX-109, a synthetic antimicrobial peptide, against methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, daptomycin-nonsusceptible, and linezolid-nonsusceptible Staphylococcus aureus. Antimicrob Agents Chemother  2012,56(8),4478-4482","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1128\/AAC.03513-14","volume":"59","author":"Nilsson A.C.","year":"2015","unstructured":"Nilsson A.C.; Janson H.; Wold H.; Fugelli A.; Andersson K.; H\u00e5kang\u00e5rd C.; Olsson P.; Olsen W.M.; LTX-109 is a novel agent for nasal decolonization of methicillin-resistant and -sensitive Staphylococcus aureus. Antimicrob Agents Chemother  2015,59(1),145-151","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1007\/s00018-011-0717-3","volume":"68","author":"Giuliani A.","year":"2011","unstructured":"Giuliani A.; Rinaldi A.C.; Beyond natural antimicrobial peptides: Multimeric peptides and other peptidomimetic approaches. Cell Mol Life Sci  2011,68(13),2255-2266","journal-title":"Cell Mol Life Sci"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"229","DOI":"10.2147\/IDR.S49229","volume":"7","author":"M\u00e9ndez-Samperio P.","year":"2014","unstructured":"M\u00e9ndez-Samperio P.; Peptidomimetics as a new generation of antimicrobial agents: Current progress. Infect Drug Resist  2014,7,229-237","journal-title":"Infect Drug Resist"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.3389\/fimmu.2020.02177","volume":"11","author":"Mercer D.K.","year":"2020","unstructured":"Mercer D.K.; O\u2019Neil D.A.; Innate inspiration: Antifungal peptides and other immunotherapeutics from the host immune response. Front Immunol  2020,11,2177-2205","journal-title":"Front Immunol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"5786","DOI":"10.1021\/jm200450h","volume":"54","author":"Isaksson J.","year":"2011","unstructured":"Isaksson J.; Brandsdal B.O.; Engqvist M.; Flaten G.E.; Svendsen J.S.M.; Stensen W.; A synthetic antimicrobial peptidomimetic (LTX 109): Stereochemical impact on membrane disruption. J Med Chem  2011,54(16),5786-5795","journal-title":"J Med Chem"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.addr.2020.12.016","volume":"170","author":"Jiang Y.","year":"2021","unstructured":"Jiang Y.; Chen Y.; Song Z.; Tan Z.; Cheng J.; Recent advances in design of antimicrobial peptides and polypeptides toward clinical translation. Adv Drug Deliv Rev  2021,170,261-280","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/lam.12792","volume":"65","author":"Saravolatz L.D.","year":"2017","unstructured":"Saravolatz L.D.; Pawlak J.; Martin H.; Saravolatz S.; Johnson L.; Wold H.; Husbyn M.; Olsen W.M.; Postantibiotic effect and postantibiotic sub-MIC effect of LTX-109 and mupirocin on Staphylococcus aureus blood isolates. Lett Appl Microbiol  2017,65(5),410-413","journal-title":"Lett Appl Microbiol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"e24122","DOI":"10.1002\/pep2.24122","volume":"111","author":"Koo H.B.","year":"2019","unstructured":"Koo H.B.; Seo J.; Antimicrobial peptides under clinical investigation. Pept Sci (Hoboken)  2019,111(5),e24122","journal-title":"Pept Sci (Hoboken)"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1517\/13543784.2014.848853","volume":"23","author":"Xu Z.Q.","year":"2014","unstructured":"Xu Z.Q.; Flavin M.T.; Flavin J.; Combating multidrug-resistant gram-negative bacterial infections. Expert Opin Investig Drugs  2014,23(2),163-182","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1021\/acscombsci.8b00088","volume":"20","author":"Rakesh K.P.","year":"2018","unstructured":"Rakesh K.P.; Marichannegowda M.H.; Srivastava S.; Chen X.; Long S.; Karthik C.S.; Mallu P.; Qin H.L.; Combating a master manipulator: Staphylococcus aureus immunomodulatory molecules as targets for combinatorial drug discovery. ACS Comb Sci  2018,20(12),681-693","journal-title":"ACS Comb Sci"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1089\/jop.2015.0098","volume":"32","author":"Kowalski R.P.","year":"2016","unstructured":"Kowalski R.P.; Romanowski E.G.; Yates K.A.; Mah F.S.; An independent evaluation of a novel peptide mimetic, brilacidin (PMX30063), for ocular anti-infective. J Ocul Pharmacol Ther  2016,32(1),23-27","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3389\/fnins.2017.00073","volume":"11","author":"Li J.","year":"2017","unstructured":"Li J.; Koh J.J.; Liu S.; Lakshminarayanan R.; Verma C.S.; Beuerman R.W.; Membrane active antimicrobial peptides: Translating mechanistic insights to design. Front Neurosci  2017,11,73-91","journal-title":"Front Neurosci"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1093\/cid\/cit152","volume":"56","author":"Boucher H.W.","year":"2013","unstructured":"Boucher H.W.; Talbot G.H.; Benjamin D.K.; Bradley J.; Guidos R.J.; Jones R.N.; Murray B.E.; Bonomo R.A.; Gilbert D.; 10 x \u201920 Progress--development of new drugs active against gram-negative bacilli: An update from the Infectious Diseases Society of America. Clin Infect Dis  2013,56(12),1685-1694","journal-title":"Clin Infect Dis"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1080\/13543776.2020.1740683","volume":"30","author":"Wang M.","year":"2020","unstructured":"Wang M.; Odom T.; Cai J.; Challenges in the development of next-generation antibiotics: Opportunities of small molecules mimicking mode of action of host-defense peptides. Expert Opin Ther Pat  2020,30(5),303-305","journal-title":"Expert Opin Ther Pat"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"315","DOI":"10.4155\/fmc.12.213","volume":"5","author":"Mercer D.K.","year":"2013","unstructured":"Mercer D.K.; O\u2019Neil D.A.; Peptides as the next generation of anti-infectives. Future Med Chem  2013,5(3),315-337","journal-title":"Future Med Chem"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"51","DOI":"10.12703\/P5-51","volume":"5","author":"Tillotson G.S.","year":"2013","unstructured":"Tillotson G.S.; Theriault N.; New and alternative approaches to tackling antibiotic resistance. F1000Prime Rep  2013,5,51-60","journal-title":"F1000Prime Rep"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12879-016-2100-3","volume":"17","author":"McCool R.","year":"2017","unstructured":"McCool R.; Gould I.M.; Eales J.; Barata T.; Arber M.; Fleetwood K.; Glanville J.; Kauf T.L.; Systematic review and network meta-analysis of tedizolid for the treatment of acute bacterial skin and skin structure infections caused by MRSA. BMC Infect Dis  2017,17(1),39","journal-title":"BMC Infect Dis"},{"key":"ref=80","first-page":"25","author":"Jorgensen D.","year":"2015","unstructured":"Jorgensen D.; Scott R.; O\u2019Riordan W.; Tack K.; A randomized, double-blind study comparing single-dose and short-course brilacidin to daptomycin in the treatment of acute bacterial skin and skin structure infections (ABSSSI 25 European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)  2015,25-28","journal-title":"25 European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/ja.2017.117","volume":"71","author":"Takahashi Y.","year":"2018","unstructured":"Takahashi Y.; Igarashi M.; Destination of aminoglycoside antibiotics in the \u2018post-antibiotic era\u2019. J Antibiot (Tokyo)  2018,71(1),4-14","journal-title":"J Antibiot (Tokyo)"},{"key":"ref=82","first-page":"523","author":"Singh G.S.","year":"2006","unstructured":"Singh G.S.;  Carbohydrate-based antibiotics: Opportunities and challenges  2006,523-559","journal-title":"Carbohydrate-based antibiotics: Opportunities and challenges"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"e00267-19","DOI":"10.1128\/AAC.00267-19","volume":"63","author":"Lakota E.A.","year":"2019","unstructured":"Lakota E.A.; Sato N.; Koresawa T.; Kondo K.; Bhavnani S.M.; Ambrose P.G.; Rubino C.M.; Population pharmacokinetic analyses for arbekacin after administration of ME1100 inhalation solution. Antimicrob Agents Chemother  2019,63(8),e00267-19","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3390\/microorganisms8020191","volume":"8","author":"Koulenti D.","year":"2020","unstructured":"Koulenti D.; Xu E.; Song A.; Sum Mok I.Y.; Karageorgopoulos D.E.; Armaganidis A.; Tsiodras S.; Lipman J.; Emerging treatment options for infections by multidrug-resistant gram-positive microorganisms. Microorganisms  2020,8(2),191-231","journal-title":"Microorganisms"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"6038","DOI":"10.26717\/BJSTR.2018.07.001536","volume":"7","author":"AB Naafs M.","year":"2018","unstructured":"AB Naafs M.; The antimicrobial peptides: Ready for clinical trials. Biomed J Sci Tech Res  2018,7(4),6038-6042","journal-title":"Biomed J Sci Tech Res"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1093\/jac\/dks213","volume":"67","author":"Appelbaum P.C.","year":"2012","unstructured":"Appelbaum P.C.; 2012 and beyond: Potential for the start of a second pre-antibiotic era? J Antimicrob Chemother  2012,67(9),2062-2068","journal-title":"J Antimicrob Chemother"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"500","DOI":"10.3390\/antibiotics2040500","volume":"2","author":"de Souza Mendes C.","year":"2013","unstructured":"de Souza Mendes C.; de Souza Antunes A.; Pipeline of known chemical classes of antibiotics. Antibiotics (Basel)  2013,2(4),500-534","journal-title":"Antibiotics (Basel)"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"3188","DOI":"10.1128\/AAC.48.8.3188-3192.2004","volume":"48","author":"Peric M.","year":"2004","unstructured":"Peric M.; Jacobs M.R.; Appelbaum P.C.; Antianaerobic activity of a novel fluoroquinolone, WCK 771, compared to those of nine other agents. Antimicrob Agents Chemother  2004,48(8),3188-3192","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1080\/13543784.2017.1385761","volume":"26","author":"Liapikou A.","year":"2017","unstructured":"Liapikou A.; Cill\u00f3niz C.; Torres A.; Investigational drugs in phase I and phase II clinical trials for the treatment of community-acquired pneumonia. Expert Opin Investig Drugs  2017,26(11),1239-1248","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.mib.2011.08.002","volume":"14","author":"Jabes D.","year":"2011","unstructured":"Jabes D.; The antibiotic RandD pipeline: An update. Curr Opin Microbiol  2011,14(5),564-569","journal-title":"Curr Opin Microbiol"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.jmii.2019.05.015","volume":"72","author":"Lipsky B.A.","year":"2019","unstructured":"Lipsky B.A.; Tsai C.Y.; Chang L.W.; Chang Y.T.; Hsu M.C.; WITHDRAWN: Nemonoxacin treatment of patients with diabetic foot infection: A pilot study. J Microbiol Immunol Infect  2019,72,397-404","journal-title":"J Microbiol Immunol Infect"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"e02095-16","DOI":"10.1128\/AAC.02095-16","volume":"61","author":"O\u2019Riordan W.","year":"2017","unstructured":"O\u2019Riordan W.; Tiffany C.; Scangarella-Oman N.; Perry C.; Hossain M.; Ashton T.; Dumont E.; Efficacy, safety, and tolerability of Gepotidacin (GSK2140944) in the treatment of patients with suspected or confirmed gram-positive acute bacterial skin and skin structure infections. Antimicrob Agents Chemother  2017,61(6),e02095-16","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"5359","DOI":"10.1128\/AAC.00723-10","volume":"54","author":"Jeong J.W.","year":"2010","unstructured":"Jeong J.W.; Jung S.J.; Lee H.H.; Kim Y.Z.; Park T.K.; Cho Y.L.; Chae S.E.; Baek S.Y.; Woo S.H.; Lee H.S.; Kwak J.H.; In vitro and in vivo activities of LCB01-0371, a new oxazolidinone. Antimicrob Agents Chemother  2010,54(12),5359-5362","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1517\/13543784.2016.1109077","volume":"25","author":"Vuong C.","year":"2016","unstructured":"Vuong C.; Yeh A.J.; Cheung G.Y.C.; Otto M.; Investigational drugs to treat methicillin-resistant Staphylococcus aureus. Expert Opin Investig Drugs  2016,25(1),73-93","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"e00451-18","DOI":"10.1128\/AAC.00451-18","volume":"62","author":"Cho Y.S.","year":"2018","unstructured":"Cho Y.S.; Lim H.S.; Lee S.H.; Cho Y.L.; Nam H.; Bae K.S.; Pharmacokinetics, pharmacodynamics, and tolerability of single-dose oral LCB01-0371, a novel oxazolidinone with broad-spectrum activity, in healthy volunteers. ntimicrob. Antimicrob Agents Chemother  2018,62(7),e00451-18","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"e01195-20","DOI":"10.1128\/AAC.01195-20","volume":"64","author":"Carvalhaes C.G.","year":"2020","unstructured":"Carvalhaes C.G.; Duncan L.R.; Wang W.; Sader H.S.; In vitro activity and potency of the novel Oxazolidinone Contezolid (MRX-I) tested against Gram-positive clinical isolates from US and Europe. Antimicrob Agents Chemother  2020,64(11),e01195-20","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"e1800560","DOI":"10.1002\/cbdv.201800560","volume":"16","author":"Li Y.G.","year":"2019","unstructured":"Li Y.G.; Wang J.X.; Zhang G.N.; Zhu M.; You X.F.; Hu X.X.; Zhang F.; Wang Y.C.; Antibacterial activity and structure\u2212 activity relationship of a series of newly synthesized Pleuromutilin derivatives. Chem Biodivers  2019,16(2),e1800560","journal-title":"Chem Biodivers"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1128\/CMR.00033-13","volume":"26","author":"Pucci M.J.","year":"2013","unstructured":"Pucci M.J.; Bush K.; Investigational antimicrobial agents of 2013. Clin Microbiol Rev  2013,26(4),792-821","journal-title":"Clin Microbiol Rev"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"a027110","DOI":"10.1101\/cshperspect.a027110","volume":"7","author":"Paukner S.","year":"2017","unstructured":"Paukner S.; Riedl R.; Pleuromutilins: Potent drugs for resistant bugs\u2014mode of action and resistance. Cold Spring Harb Perspect Med  2017,7(1),a027110","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1039\/C6MD00232C","volume":"7","author":"Jones J.A.","year":"2016","unstructured":"Jones J.A.; Virga K.G.; Gumina G.; Hevener K.E.; Recent advances in the rational design and optimization of antibacterial agents. MedChemComm  2016,7(9),1694-1715","journal-title":"MedChemComm"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1080\/14787210.2019.1667229","volume":"17","author":"Giacobbe D.R.","year":"2019","unstructured":"Giacobbe D.R.; De Rosa F.G.; Del Bono V.; Grossi P.A.; Pea F.; Petrosillo N.; Rossolini G.M.; Tascini C.; Tumbarello M.; Viale P.; Bassetti M.; Ceftobiprole: Drug evaluation and place in therapy. Expert Rev Anti Infect Ther  2019,17(9),689-698","journal-title":"Expert Rev Anti Infect Ther"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1080\/17460441.2016.1187597","volume":"11","author":"Parkes A.L.","year":"2016","unstructured":"Parkes A.L.; Yule I.A.; Hybrid antibiotics \u2013 clinical progress and novel designs. Expert Opin Drug Discov  2016,11(7),665-680","journal-title":"Expert Opin Drug Discov"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1128\/AAC.05532-11","volume":"56","author":"Blais J.","year":"2012","unstructured":"Blais J.; Lewis S.R.; Krause K.M.; Benton B.M.; Antistaphylococcal activity of TD-1792, a multivalent glycopeptide-cephalosporin antibiotic. Antimicrob Agents Chemother  2012,56(3),1584-1587","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"3799","DOI":"10.1128\/AAC.00452-10","volume":"54","author":"Leuthner K.D.","year":"2010","unstructured":"Leuthner K.D.; Vidaillac C.; Cheung C.M.; Rybak M.J.; In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates. Antimicrob Agents Chemother  2010,54(9),3799-3803","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1128\/AAC.05382-11","volume":"56","author":"Hegde S.S.","year":"2012","unstructured":"Hegde S.S.; Okusanya O.O.; Skinner R.; Shaw J.P.; Obedencio G.; Ambrose P.G.; Blais J.; Bhavnani S.M.; Pharmacodynamics of TD-1792, a novel glycopeptide-cephalosporin heterodimer antibiotic used against Gram-positive bacteria, in a neutropenic murine thigh model. Antimicrob Agents Chemother  2012,56(3),1578-1583","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"6924","DOI":"10.1021\/acs.joc.7b02318","volume":"83","author":"Itoh H.","year":"2018","unstructured":"Itoh H.; Tokumoto K.; Kaji T.; Paudel A.; Panthee S.; Hamamoto H.; Sekimizu K.; Inoue M.; Total synthesis and biological mode of action of WAP-8294A2: A menaquinone-targeting antibiotic. J Org Chem  2018,83(13),6924-6935","journal-title":"J Org Chem"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"6680","DOI":"10.1021\/ja970895o","volume":"119","author":"Kato A.","year":"1997","unstructured":"Kato A.; Nakaya S.; Ohashi Y.; Hirata H.; Fujii K.; Harada K.; WAP-8294A2, a novel anti-MRSA antibiotic produced by Lysobacter sp. J Am Chem Soc  1997,119(28),6680-6681","journal-title":"J Am Chem Soc"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/ja.2011.9","volume":"64","author":"Kato A.","year":"2011","unstructured":"Kato A.; Hirata H.; Ohashi Y.; Fujii K.; Mori K.; Harada K.; A new anti-MRSA antibiotic complex, WAP-8294A II. Structure characterization of minor components by ESI LCMS and MS\/MS. J Antibiot (Tokyo)  2011,64(5),373-379","journal-title":"J Antibiot (Tokyo)"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.3389\/fmicb.2019.01230","volume":"10","author":"Ling J.","year":"2019","unstructured":"Ling J.; Zhu R.; Laborda P.; Jiang T.; Jia Y.; Zhao Y.; Liu F.; LbDSF, the Lysobacter brunescens quorum sensing system diffusible signalling factor, regulates anti-xanthomonas XSAC biosynthesis, colony morphology, and surface motility. Front Microbiol  2019,10,1230-1244","journal-title":"Front Microbiol"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1128\/AAC.01741-15","volume":"60","author":"Hafkin B.","year":"2016","unstructured":"Hafkin B.; Kaplan N.; Murphy B.; Efficacy and safety of AFN-1252, the first Staphylococcus-specific antibacterial agent, in the treatment of acute bacterial skin and skin structure infections, including those in patients with significant comorbidities. Antimicrob Agents Chemother  2016,60(3),1695-1701","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41429-020-0291-8","volume":"73","author":"Butler M.S.","year":"2020","unstructured":"Butler M.S.; Paterson D.L.; Antibiotics in the clinical pipeline in October 2019. J Antibiot (Tokyo)  2020,73(6),329-364","journal-title":"J Antibiot (Tokyo)"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"115040","DOI":"10.1016\/j.diagmicrobio.2020.115040","volume":"97","author":"Fisher C.R.","year":"2020","unstructured":"Fisher C.R.; Schmidt-Malan S.M.; Ma Z.; Yuan Y.; He S.; Patel R.; In vitro activity of TNP-2092 against periprosthetic joint infection\u2013associated staphylococci. Diagn Microbiol Infect Dis  2020,97(3),115040-115065","journal-title":"Diagn Microbiol Infect Dis"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1097\/QCO.0000000000000539","volume":"32","author":"Motley M.P.","year":"2019","unstructured":"Motley M.P.; Banerjee K.; Fries B.C.; Monoclonal antibody-based therapies for bacterial infections. Curr Opin Infect Dis  2019,32(3),210-216","journal-title":"Curr Opin Infect Dis"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"e02588-18","DOI":"10.1128\/AAC.02588-18","volume":"63","author":"Peck M.","year":"2019","unstructured":"Peck M.; Rothenberg M.E.; Deng R.; Lewin-Koh N.; She G.; Kamath A.V.; Carrasco-Triguero M.; Saad O.; Castro A.; Teufel L.; Dickerson D.S.; Leonardelli M.; Tavel J.A.; A phase 1, randomized, single-ascending-dose study to investigate the safety, tolerability, and pharmacokinetics of DSTA4637S, an anti-Staphylococcus aureus thiomab antibody-antibiotic conjugate, in healthy volunteers. Antimicrob Agents Chemother  2019,63(6),e02588-18","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"S542","DOI":"10.1093\/cid\/cir170","volume":"52","author":"Fernandes P.","year":"2011","unstructured":"Fernandes P.; Pereira D.; Efforts to support the development of fusidic acid in the United States. Clin Infect Dis  2011,52(7)(Suppl. 7),S542-S546","journal-title":"Clin Infect Dis"},{"key":"ref=116","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/978-981-13-1577-0_13","author":"Shukla M.","year":"2018","unstructured":"Shukla M.; Soni I.; Dasgupta A.; Chopra S.; Drugs under preclinical and clinical testing for the treatment of infections caused due to Staphylococcus aureus.  An update, in infectious diseases and your health  2018,239-255","journal-title":"An update, in infectious diseases and your health"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.diagmicrobio.2009.10.014","volume":"66","author":"Biedenbach D.J.","year":"2010","unstructured":"Biedenbach D.J.; Rhomberg P.R.; Mendes R.E.; Jones R.N.; Spectrum of activity, mutation rates, synergistic interactions, and the effects of pH and serum proteins for fusidic acid (CEM-102). Diagn Microbiol Infect Dis  2010,66(3),301-307","journal-title":"Diagn Microbiol Infect Dis"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"5269","DOI":"10.1128\/AAC.03389-14","volume":"58","author":"Noeske J.","year":"2014","unstructured":"Noeske J.; Huang J.; Olivier N.B.; Giacobbe R.A.; Zambrowski M.; Cate J.H.D.; Synergy of streptogramin antibiotics occurs independently of their effects on translation. Antimicrob Agents Chemother  2014,58(9),5269-5279","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1517\/14728214.2013.813480","volume":"18","author":"Liapikou A.","year":"2013","unstructured":"Liapikou A.; Torres A.; Emerging drugs on methicillin-resistant Staphylococcus aureus. Expert Opin Emerg Drugs  2013,18(3),291-305","journal-title":"Expert Opin Emerg Drugs"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1128\/AAC.01159-10","volume":"55","author":"Pankuch G.A.","year":"2011","unstructured":"Pankuch G.A.; Lin G.; Clark C.; Appelbaum P.C.; Time-kill activity of the streptogramin NXL 103 against gram-positive and -negative bacteria. Antimicrob Agents Chemother  2011,55(4),1787-1791","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=121","first-page":"225","volume":"11","author":"Politano A.D.","year":"2010","unstructured":"Politano A.D.; Sawyer R.G.; NXL-103, a combination of flopristin and linopristin, for the potential treatment of bacterial infections including community-acquired pneumonia and MRSA. Curr Opin Investig Drugs  2010,11(2),225-236","journal-title":"Curr Opin Investig Drugs"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"6568","DOI":"10.1128\/AAC.01464-15","volume":"59","author":"Lepak A.J.","year":"2015","unstructured":"Lepak A.J.; Parhi A.; Madison M.; Marchillo K.; VanHecker J.; Andes D.R.; In vivo pharmacodynamic evaluation of an FtsZ Inhibitor, TXA-709, and its active metabolite, TXA-707, in a murine neutropenic thigh infection model. Antimicrob Agents Chemother  2015,59(10),6568-6574","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/s41579-020-0340-0","volume":"18","author":"Theuretzbacher U.","year":"2020","unstructured":"Theuretzbacher U.; Bush K.; Harbarth S.; Paul M.; Rex J.H.; Tacconelli E.; Thwaites G.E.; Critical analysis of antibacterial agents in clinical development. Nat Rev Microbiol  2020,18(5),286-298","journal-title":"Nat Rev Microbiol"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.4155\/fmc-2020-0225","volume":"12","author":"Stephens L.J.","year":"2020","unstructured":"Stephens L.J.; Werrett M.V.; Sedgwick A.C.; Bull S.D.; Andrews P.C.; Antimicrobial innovation: A current update and perspective on the antibiotic drug development pipeline. Future Med Chem  2020,12(22),2035-2065","journal-title":"Future Med Chem"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"4845","DOI":"10.1128\/AAC.00708-15","volume":"59","author":"Kaul M.","year":"2015","unstructured":"Kaul M.; Mark L.; Zhang Y.; Parhi A.K.; Lyu Y.L.; Pawlak J.; Saravolatz S.; Saravolatz L.D.; Weinstein M.P.; LaVoie E.J.; Pilch D.S.; TXA709, an FtsZ-targeting benzamide prodrug with improved pharmacokinetics and enhanced in vivo efficacy against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother  2015,59(8),4845-4855","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1128\/AAC.01779-12","volume":"57","author":"Naderer O.J.","year":"2013","unstructured":"Naderer O.J.; Dumont E.; Zhu J.; Kurtinecz M.; Jones L.S.; Single-dose safety, tolerability, and pharmacokinetics of the antibiotic GSK1322322, a novel peptide deformylase inhibitor. Antimicrob Agents Chemother  2013,57(5),2005-2009","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"6518","DOI":"10.1128\/AAC.03360-14","volume":"58","author":"Corey R.","year":"2014","unstructured":"Corey R.; Naderer O.J.; O\u2019Riordan W.D.; Dumont E.; Jones L.S.; Kurtinecz M.; Zhu J.Z.; Safety, tolerability, and efficacy of GSK1322322 in the treatment of acute bacterial skin and skin structure infections. Antimicrob Agents Chemother  2014,58(11),6518-6527","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"418","DOI":"10.3390\/antibiotics9070418","volume":"9","author":"Alm R.A.","year":"2020","unstructured":"Alm R.A.; Lahiri S.D.; Narrow-spectrum antibacterial agents\u2014benefits and challenges. Antibiotics (Basel)  2020,9(7),418-426","journal-title":"Antibiotics (Basel)"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.mib.2021.02.001","volume":"61","author":"Page J.E.","year":"2021","unstructured":"Page J.E.; Walker S.; Natural products that target the cell envelope. Curr Opin Microbiol  2021,61,16-24","journal-title":"Curr Opin Microbiol"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"e03117-20","DOI":"10.1128\/JCM.03117-20","volume":"59","author":"Traczewski M.M.","year":"2021","unstructured":"Traczewski M.M.; Ambler J.E.; Schuch R.; Determination of MIC quality control parameters for Exebacase, a novel lysin with anti-staphylococcal activity. J Clin Microbiol  2021,59(7),e03117-20","journal-title":"J Clin Microbiol"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"e01078-19","DOI":"10.1128\/AAC.01078-19","volume":"63","author":"Watson A.","year":"2019","unstructured":"Watson A.; Oh J.T.; Sauve K.; Bradford P.A.; Cassino C.; Schuch R.; Antimicrobial activity of exebacase (lysin CF-301) against the most common causes of infective endocarditis. Antimicrob Agents Chemother  2019,63(10),e01078-19","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"e00731-18","DOI":"10.1128\/AAC.00731-18","volume":"62","author":"Kim N.H.","year":"2018","unstructured":"Kim N.H.; Park W.B.; Cho J.E.; Choi Y.J.; Choi S.J.; Jun S.Y.; Kang C.K.; Song K.H.; Choe P.G.; Bang J.H.; Kim E.S.; Park S.W.; Kim N.J.; Oh M.; Kim H.B.; Effects of phage endolysin SAL200 combined with antibiotics on Staphylococcus aureus infection. Antimicrob Agents Chemother  2018,62(10),e00731-18","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"e00229-19","DOI":"10.1128\/JCM.00229-19","volume":"57","author":"Caflisch K.M.","year":"2019","unstructured":"Caflisch K.M.; Patel R.; Implications of bacteriophage-and bacteriophage component-based therapies for the clinical microbiology laboratory. J Clin Microbiol  2019,57(8),e00229-19","journal-title":"J Clin Microbiol"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1111\/1440-1681.12613","volume":"43","author":"Jun S.Y.","year":"2016","unstructured":"Jun S.Y.; Jung G.M.; Yoon S.J.; Youm S.Y.; Han H.Y.; Lee J.H.; Kang S.H.; Pharmacokinetics of the phage endolysin-based candidate drug  200 in monkeys and its appropriate intravenous dosing period. Clin Exp Pharmacol Physiol  2016,43(10),1013-1016","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1093\/jac\/dky365","volume":"73","author":"Channabasappa S.","year":"2018","unstructured":"Channabasappa S.; Chikkamadaiah R.; Durgaiah M.; Kumar S.; Ramesh K.; Sreekanthan A.; Sriram B.; Efficacy of chimeric ectolysin P128 in drug-resistant Staphylococcus aureus bacteraemia in mice. J Antimicrob Chemother  2018,73(12),3398-3404","journal-title":"J Antimicrob Chemother"},{"key":"ref=136","unstructured":"Safety and efficacy of an antibacterial protein molecule applied topically to the nostrils of volunteers and patients.  ClinicalTrials.gov Available From:  https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01746654"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1080\/21505594.2017.1295205","volume":"8","author":"Bagnoli F.","year":"2017","unstructured":"Bagnoli F.; Staphylococcus aureus toxin antibodies: Good companions of antibiotics and vaccines. Virulence  2017,8(7),1037-1042","journal-title":"Virulence"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"e0190537","DOI":"10.1371\/journal.pone.0190537","volume":"13","author":"Varshney A.K.","year":"2018","unstructured":"Varshney A.K.; Kuzmicheva G.A.; Lin J.; Sunley K.M.; Bowling R.A.; Kwan T.Y.; Mays H.R.; Rambhadran A.; Zhang Y.; Martin R.L.; Cavalier M.C.; Simard J.; Shivaswamy S.; A natural human monoclonal antibody targeting Staphylococcus Protein A protects against Staphylococcus aureus bacteremia. PLoS One  2018,13(1),e0190537","journal-title":"PLoS One"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1517\/13543784.2016.1168803","volume":"25","author":"Falc\u00f3 V.","year":"2016","unstructured":"Falc\u00f3 V.; Burgos J.; Papiol E.; Ferrer R.; Almirante B.; Investigational drugs in phase I and phase II clincial trials for the treatment of hospital-acquired pneumonia. Expert Opin Investig Drugs  2016,25(6),653-665","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3390\/antib7010005","volume":"7","author":"Wang-Lin S.","year":"2018","unstructured":"Wang-Lin S.; Balthasar J.; Pharmacokinetic and pharmacodynamic considerations for the use of monoclonal antibodies in the treatment of bacterial infections. Antibodies (Basel)  2018,7(1),5-25","journal-title":"Antibodies (Basel)"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1007\/s40265-020-01402-z","volume":"80","author":"Vignon P.","year":"2020","unstructured":"Vignon P.; Laterre P.F.; Daix T.; Fran\u00e7ois B.; New agents in development for sepsis: Any reason for hope? Drugs  2020,80(17),1751-1761","journal-title":"Drugs"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"5312","DOI":"10.1128\/AAC.00357-16","volume":"60","author":"Tabor D.E.","year":"2016","unstructured":"Tabor D.E.; Yu L.; Mok H.; Tkaczyk C.; Sellman B.R.; Wu Y.; Oganesyan V.; Slidel T.; Jafri H.; McCarthy M.; Bradford P.; Esser M.T.; Staphylococcus aureus alpha-toxin is conserved among diverse hospital respiratory isolates collected from a global surveillance study and is neutralized by monoclonal antibody MEDI4893. Antimicrob Agents Chemother  2016,60(9),5312-5321","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/S1473-3099(20)30995-6","volume":"21","author":"Fran\u00e7ois B.","year":"2021","unstructured":"Fran\u00e7ois B.; Jafri H.S.; Chastre J.; S\u00e1nchez-Garc\u00eda M.; Eggimann P.; Dequin P.F.; Huberlant V.; Vi\u00f1a Soria L.; Boulain T.; Bretonni\u00e8re C.; Pugin J.; Trenado J.; Hernandez Padilla A.C.; Ali O.; Shoemaker K.; Ren P.; Coenjaerts F.E.; Ruzin A.; Barraud O.; Timbermont L.; Lammens C.; Pierre V.; Wu Y.; Vignaud J.; Colbert S.; Bellamy T.; Esser M.T.; Dubovsky F.; Bonten M.J.; Goossens H.; Laterre P.F.; Chochrad D.; Dive A.; Foret F.; Simon M.; Spapen H.; Creteur J.; Bouckaert Y.; Biston P.; Bourgeois M.; Novacek M.; Vymazal T.; Svoboda P.; Pachl J.; Sramek V.; Hanauer M.; Hruby T.; Balik M.; Suchy T.; Lepape A.; Argaud L.; Dailler F.; Desachy A.; Guitton C.; Mercat A.; Meziani F.; Navellou J-C.; Robert R.; Souweine B.; Tadie J-M.; Maamar A.; Annane D.; Tamion F.; Gros A.; Nseir S.; Schwebel C.; Francony G.; Lefrant J-Y.; Schneider F.; Gr\u00fcndling M.; Motsch J.; Reill L.; Rolfes C.; Welte T.; Cornely O.; Bloos F.; Deja M.; Schmidt K.; Wappler F.; Meier-Hellmann A.; Komnos A.; Bekos V.; Koulouras V.; Soultati I.; Baltopoulos G.; Filntisis G.; Zakynthinos E.; Zakynthinos S.; Pnevmatikos I.; Kr\u00e9mer I.; Szentkereszty Z.; Sarkany A.; Marjanek Z.; Moura P.; Pintado Delgado M.C.; Montejo Gonz\u00e1lez J.C.; Ramirez P.; Torres Marti A.; Valia J.C.; Lorente J.; Loza Vazquez A.; De Pablo Sanchez R.; Escudero D.; Ferrer Roca R.; Pagani J-L.; Maggiorini M.; Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): A multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial. Lancet Infect Dis  2021,21(9),1313-1323","journal-title":"Lancet Infect Dis"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1517\/14656566.7.14.1957","volume":"7","author":"Jacobs M.R.","year":"2006","unstructured":"Jacobs M.R.; Appelbaum P.C.; Nadifloxacin: A quinolone for topical treatment of skin infections and potential for systemic use of its active isomer, WCK 771. Expert Opin Pharmacother  2006,7(14),1957-1966","journal-title":"Expert Opin Pharmacother"},{"key":"ref=145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10408347.2019.1565983","volume":"50","author":"Lautre C.","year":"2020","unstructured":"Lautre C.; Sharma S.; Sahu J.K.; Chemistry, biological properties and analytical methods of Levonadifloxacin:A review. Crit Rev Anal Chem  2020,50,1-9","journal-title":"Crit Rev Anal Chem"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"307","DOI":"10.4103\/ijmm.IJMM_20_307","volume":"38","author":"Baliga S.","year":"2020","unstructured":"Baliga S.; Mamtora D.K.; Gupta V.; Shanmugam P.; Biswas S.; Mukherjee D.N.; Shenoy S.; Assessment of antibacterial activity of levonadifloxacin against contemporary gram-positive clinical isolates collected from various Indian hospitals using disk-diffusion assay. Indian J Med Microbiol  2020,38(3-4),307-312","journal-title":"Indian J Med Microbiol"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ijmmb.2022.11.005","volume":"41","author":"Veeraraghavan B.","year":"2023","unstructured":"Veeraraghavan B.; Bakthavatchalam Y.D.; Manesh A.; Lal B.; Swaminathan S.; Ansari A.; Subbareddy K.; Rangappa P.; Choudhuri A.H.; Nagvekar V.; Mehta Y.; Appalaraju B.; Baveja S.; Baliga S.; Shenoy S.; Bhardwaj R.; Kongre V.; Dattatraya G.S.; Verma B.; Mukherjee D.N.; Gupta S.; Shanmugam P.; Iravane J.; Mishra S.R.; Barman P.; Chopra S.; Hariharan M.; Surpam R.; Pratap R.; Turbadkar D.; Taklikar S.; India-discovered levonadifloxacin and alalevonadifloxacin: A review on susceptibility testing methods, CLSI quality control and breakpoints along with a brief account of their emerging therapeutic profile as a novel standard-of-care. Indian J Med Microbiol  2023,41(3),71-80","journal-title":"Indian J Med Microbiol"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"e02297-17","DOI":"10.1128\/AAC.02297-17","volume":"62","author":"Rodvold K.A.","year":"2018","unstructured":"Rodvold K.A.; Gotfried M.H.; Chugh R.; Gupta M.; Yeole R.; Patel A.; Bhatia A.; Intrapulmonary pharmacokinetics of Levonadifloxacin following oral administration of Alalevonadifloxacin to healthy adult subjects. Antimicrob Agents Chemother  2018,62(3),e02297-17","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"119","DOI":"10.2147\/IDR.S105620","volume":"9","author":"Jones T.","year":"2016","unstructured":"Jones T.; Johnson S.; DiMondi V.P.; Wilson D.T.; Focus on JNJ-Q2, a novel fluoroquinolone, for the management of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Infect Drug Resist  2016,9,119-128","journal-title":"Infect Drug Resist"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"5790","DOI":"10.1128\/AAC.05044-11","volume":"55","author":"Covington P.","year":"2011","unstructured":"Covington P.; Davenport J.M.; Andrae D.; O\u2019Riordan W.; Liverman L.; McIntyre G.; Almenoff J.; Randomized, double-blind, phase II, multicenter study evaluating the safety\/tolerability and efficacy of JNJ-Q2, a novel fluoroquinolone, compared with linezolid for treatment of acute bacterial skin and skin structure infection. Antimicrob Agents Chemother  2011,55(12),5790-5797","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=151","first-page":"1","author":"Chang L-W.","year":"2019","unstructured":"Chang L-W.; Hsu M-C.; Zhang Y-Y.;  Staphylococcus and Streptococcus  2019,1-95","journal-title":"Staphylococcus and Streptococcus"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12941-016-0150-4","volume":"15","author":"Kocsis B.","year":"2016","unstructured":"Kocsis B.; Domokos J.; Szabo D.; Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin. Ann Clin Microbiol Antimicrob  2016,15(1),34-42","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.jmii.2018.11.006","volume":"52","author":"Cheng S.L.","year":"2019","unstructured":"Cheng S.L.; Wu R.G.; Chuang Y.C.; Perng W.C.; Tsao S.M.; Chang Y.T.; Chang L.W.; Hsu M.C.; Integrated safety summary of phase II and III studies comparing oral nemonoxacin and levofloxacin in community-acquired pneumonia. J Microbiol Immunol Infect  2019,52(5),743-751","journal-title":"J Microbiol Immunol Infect"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1586\/14787210.2014.894881","volume":"12","author":"Lai C.C.","year":"2014","unstructured":"Lai C.C.; Lee K.Y.; Lin S.W.; Chen Y.H.; Kuo H.Y.; Hung C.C.; Hsueh P.R.; Nemonoxacin (TG-873870) for treatment of community-acquired pneumonia. Expert Rev Anti Infect Ther  2014,12(4),401-417","journal-title":"Expert Rev Anti Infect Ther"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"4915","DOI":"10.1128\/AAC.00078-09","volume":"53","author":"Adam H.J.","year":"2009","unstructured":"Adam H.J.; Laing N.M.; King C.R.; Lulashnyk B.; Hoban D.J.; Zhanel G.G.; In vitro activity of nemonoxacin, a novel non fluorinated quinolone, against 2,440 clinical isolates. Antimicrob Agents Chemother  2009,53(11),4915-4920","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.jmii.2015.09.005","volume":"50","author":"Liu Y.","year":"2017","unstructured":"Liu Y.; Zhang Y.; Wu J.; Zhu D.; Sun S.; Zhao L.; Wang X.; Liu H.; Ren Z.; Wang C.; Xiu Q.; Xiao Z.; Cao Z.; Cui S.; Yang H.; Liang Y.; Chen P.; Lv Y.; Hu C.; Lv X.; Liu S.; Kuang J.; Li J.; Wang D.; Chang L.; A randomized, double-blind, multicenter Phase II study comparing the efficacy and safety of oral nemonoxacin with oral levofloxacin in the treatment of community-acquired pneumonia. J Microbiol Immunol Infect  2017,50(6),811-820","journal-title":"J Microbiol Immunol Infect"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1128\/AAC.46.4.1080-1085.2002","volume":"46","author":"Aoki H.","year":"2002","unstructured":"Aoki H.; Ke L.; Poppe S.M.; Poel T.J.; Weaver E.A.; Gadwood R.C.; Thomas R.C.; Shinabarger D.L.; Ganoza M.C.; Oxazolidinone antibiotics target the P site on Escherichia coli ribosomes. Antimicrob Agents Chemother  2002,46(4),1080-1085","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1016\/j.clinthera.2018.10.007","volume":"40","author":"Cho Y.S.","year":"2018","unstructured":"Cho Y.S.; Lim H.S.; Cho Y.L.; Nam H.S.; Bae K.S.; Multiple-dose safety, tolerability, pharmacokinetics, and pharmacodynamics of oral LCB01-0371 in healthy male volunteers. Clin Ther  2018,40(12),2050-2064","journal-title":"Clin Ther"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1002\/med.21798","volume":"41","author":"Egorova A.","year":"2021","unstructured":"Egorova A.; Jackson M.; Gavrilyuk V.; Makarov V.; Pipeline of anti Mycobacterium abscessus small molecules: Repurposable drugs and promising novel chemical entities. Med Res Rev  2021,41(4),2350-2387","journal-title":"Med Res Rev"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.trsl.2020.03.007","volume":"220","author":"Shetye G.S.","year":"2020","unstructured":"Shetye G.S.; Franzblau S.G.; Cho S.; New tuberculosis drug targets, their inhibitors, and potential therapeutic impact. Transl Res  2020,220(4),68-97","journal-title":"Transl Res"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.clinthera.2018.11.009","volume":"41","author":"Cho Y.S.","year":"2019","unstructured":"Cho Y.S.; Lim H.S.; Han S.; Yoon S.K.; Kim H.; Cho Y.L.; Nam H.S.; Bae K.S.; Single-dose intravenous safety, tolerability, and pharmacokinetics and absolute bioavailability of LCB01-0371. Clin Ther  2019,41(1),92-106","journal-title":"Clin Ther"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.3390\/app10072211","volume":"10","author":"Cho Y.L.","year":"2020","unstructured":"Cho Y.L.; Jang J.; Development of delpazolid for the treatment of tuberculosis. Appl Sci (Basel)  2020,10(7),2211","journal-title":"Appl Sci (Basel)"},{"key":"ref=163","author":"Gao X.","year":"2020","unstructured":"Gao X.; Zhao W.; Huo F.; Jiang G.; Dong L.; Zhao L.; Wang F.; Yu X.; Huang H.; In vitro efficacy comparison of Linezolid, Tedizolid, Sutezolid and Delpazolid against rapid growing Mycobacteria isolated in Beijing, China. BioRxiv  2020","journal-title":"BioRxiv"},{"key":"ref=164","first-page":"1123","volume":"72","author":"Kaku N.","year":"2017","unstructured":"Kaku N.; Morinaga Y.; Takeda K.; Kosai K.; Uno N.; Hasegawa H.; Miyazaki T.; Izumikawa K.; Mukae H.; Yanagihara K.; Efficacy and pharmacokinetics of ME1100, a novel optimized formulation of arbekacin for inhalation, compared with amikacin in a murine model of ventilator-associated pneumonia caused by Pseudomonas aeruginosa. J Antimicrob Chemother  2017,72(4),1123-1128","journal-title":"J Antimicrob Chemother"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"4351","DOI":"10.2147\/DDDT.S229882","volume":"13","author":"Bhagwat S.S.","year":"2019","unstructured":"Bhagwat S.S.; Nandanwar M.; Kansagara A.; Patel A.; Takalkar S.; Chavan R.; Hariharan P.; Yeole R.; Deshpande P.; Bhavsar S.; Bhatia A.; Ahdal J.; Jain R.; Patel M.; Levonadifloxacin, a novel broad-spectrum anti-MRSA benzoquinolizine quinolone agent: Review of current evidence. Drug Des Devel Ther  2019,13,4351-4365","journal-title":"Drug Des Devel Ther"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1128\/AAC.04039-14","volume":"59","author":"Wu X.","year":"2015","unstructured":"Wu X.; Zhang J.; Guo B.; Zhang Y.; Yu J.; Cao G.; Chen Y.; Zhu D.; Ye X.; Wu J.; Shi Y.; Chang L.; Chang Y.; Tsai C.; Pharmacokinetics and pharmacodynamics of multiple-dose intravenous nemonoxacin in healthy Chinese volunteers. Antimicrob Agents Chemother  2015,59(3),1446-1454","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"683","DOI":"10.3109\/00498254.2015.1112933","volume":"46","author":"Negash K.","year":"2016","unstructured":"Negash K.; Andonian C.; Felgate C.; Chen C.; Goljer I.; Squillaci B.; Nguyen D.; Pirhalla J.; Lev M.; Schubert E.; Tiffany C.; Hossain M.; Ho M.; The metabolism and disposition of GSK2140944 in healthy human subjects. Xenobiotica  2016,46(8),683-702","journal-title":"Xenobiotica"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1093\/jac\/dkx367","volume":"73","author":"Choi Y.","year":"2018","unstructured":"Choi Y.; Lee S.W.; Kim A.; Jang K.; Nam H.; Cho Y.L.; Yu K.S.; Jang I.J.; Chung J.Y.; Safety, tolerability and pharmacokinetics of 21 day multiple oral administration of a new oxazolidinone antibiotic, LCB01-0371, in healthy male subjects. J Antimicrob Chemother  2018,73(1),183-190","journal-title":"J Antimicrob Chemother"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"e02181-16","DOI":"10.1128\/AAC.02181-16","volume":"61","author":"Eckburg P.B.","year":"2017","unstructured":"Eckburg P.B.; Ge Y.; Hafkin B.; Single-and multiple-dose study to determine the safety, tolerability, pharmacokinetics, and food effect of oral MRX-I versus Linezolid in healthy adult subjects. Antimicrob Agents Chemother  2017,61(4),e02181-16","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=170","first-page":"26","volume":"36","author":"Yang D.","year":"2015","unstructured":"Yang D.; Chen L.; Lai L.; Ren M.; Zhang G.; Pan Z.; Fang B.; Research on pharmacokinetics and bioavailability of pleuromutilin derivative BC-7013 in chickens. Zhongguo Nongye Daxue Xuebao  2015,36(4),26-31","journal-title":"Zhongguo Nongye Daxue Xuebao"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1093\/jac\/dkv442","volume":"71","author":"Zeitlinger M.","year":"2016","unstructured":"Zeitlinger M.; Schwameis R.; Burian A.; Burian B.; Matzneller P.; M\u00fcller M.; Wicha W.W.; Strickmann D.B.; Prince W.; Simultaneous assessment of the pharmacokinetics of a pleuromutilin, lefamulin, in plasma, soft tissues and pulmonary epithelial lining fluid. J Antimicrob Chemother  2016,71(4),1022-1026","journal-title":"J Antimicrob Chemother"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1128\/AAC.48.7.2570-2575.2004","volume":"48","author":"Schmitt-Hoffmann A.","year":"2004","unstructured":"Schmitt-Hoffmann A.; Roos B.; Schleimer M.; Sauer J.; Man A.; Nashed N.; Brown T.; Perez A.; Weidekamm E.; Kov\u00e1cs P.; Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob Agents Chemother  2004,48(7),2570-2575","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"5476","DOI":"10.1128\/AAC.00712-12","volume":"56","author":"Stryjewski M.E.","year":"2012","unstructured":"Stryjewski M.E.; Potgieter P.D.; Li Y.P.; Barriere S.L.; Churukian A.; Kingsley J.; Corey G.R.; TD-1792 versus vancomycin for treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother  2012,56(11),5476-5483","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=174","author":"Kaplan N.","year":"2014","unstructured":"Kaplan N.; Hafkin B. 2014.; Preclinical pharmacokinetics and efficacy of Debio 1450 (Previously AFN-1720), a prodrug of the Staphylococcocal-specific Antibiotic Debio 1452 (Previously AFN-1252). In: 24 European Congress of Clinical Microbiology and Infectious Diseases (ECCMID).  2014"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"131","DOI":"10.2217\/17460913.4.2.131","volume":"4","author":"Morgan A.","year":"2009","unstructured":"Morgan A.; Cofer C.; Stevens D.L.; Iclaprim: A novel dihydrofolate reductase inhibitor for skin and soft tissue infections. Future Microbiol  2009,4(2),131-144","journal-title":"Future Microbiol"},{"key":"ref=176","author":"Weiss W.","unstructured":"Weiss W.; Pulse M.; Nguyen P.; Ma Z.;   In vivo efficacy of dual-action molecule TNP-2092 in mouse H. pylori infection model as compared to triple therapies and distribution within the gastric mucosal layer. In: American Society of Microbiology General Meeting, Poster. 2016, pp. 460"},{"key":"ref=177","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1080\/19420862.2016.1229722","volume":"8","author":"Zhou C.","year":"2016","unstructured":"Zhou C.; Lehar S.; Gutierrez J.; Rosenberger C.M.; Ljumanovic N.; Dinoso J.; Koppada N.; Hong K.; Baruch A.; Carrasco-Triguero M.; Saad O.; Mariathasan S.; Kamath A.V.; Pharmacokinetics and pharmacodynamics of DSTA4637A: A novel THIOMAB\u2122 antibody antibiotic conjugate against Staphylococcus aureus in mice. MAbs  2016,8(8),1612-1619","journal-title":"MAbs"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"S504","DOI":"10.1093\/cid\/cir174","volume":"52","author":"Still J.G.","year":"2011","unstructured":"Still J.G.; Clark K.; Degenhardt T.P.; Scott D.; Fernandes P.; Gutierrez M.J.; Pharmacokinetics and safety of single, multiple, and loading doses of fusidic acid in healthy subjects. Clin Infect Dis  2011,52(7)(Suppl. 7),S504-S512","journal-title":"Clin Infect Dis"},{"key":"ref=179","doi-asserted-by":"publisher","first-page":"3914","DOI":"10.1128\/AAC.00587-06","volume":"50","author":"Pankuch G.A.","year":"2006","unstructured":"Pankuch G.A.; Hoellman D.; Bryskier A.; Lowther J.; Appelbaum P.C.; Effects of various media on the activity of NXL103 (formerly XRP 2868), a new oral streptogramin, against Haemophilus influenzae. Antimicrob Agents Chemother  2006,50(11),3914-3916","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=180","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1128\/AAC.50.1.243-249.2006","volume":"50","author":"Andes D.","year":"2006","unstructured":"Andes D.; Craig W.A.; Pharmacodynamics of a new streptogramin, XRP 2868, in murine thigh and lung infection models. Antimicrob Agents Chemother  2006,50(1),243-249","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=181","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1002\/jcph.150","volume":"53","author":"Naderer O.J.","year":"2013","unstructured":"Naderer O.J.; Jones L.S.; Zhu J.; Kurtinecz M.; Dumont E.; Safety, tolerability, and pharmacokinetics of oral and intravenous administration of GSK1322322, a peptide deformylase inhibitor. J Clin Pharmacol  2013,53(11),1168-1176","journal-title":"J Clin Pharmacol"},{"key":"ref=182","doi-asserted-by":"publisher","DOI":"10.26226\/morressier.56ebbf52d462b80296c97eca","author":"Cassino C.","year":"2016","unstructured":"Cassino C.; Murphy M.; Boyle J.; Rotolo J.; Wittekind M.; Results of the first in human study of lysin CF-301 evaluating the safety, tolerability and pharmacokinetic profile in healthy volunteers proceedings of the 26 European congress of clinical microbiology and infectious diseases, Amsterdam, The Netherlands  2016","journal-title":"proceedings of the 26 European congress of clinical microbiology and infectious diseases, Amsterdam, The Netherlands"},{"key":"ref=183","doi-asserted-by":"publisher","first-page":"e02629-16","DOI":"10.1128\/AAC.02629-16","volume":"61","author":"Jun S.Y.","year":"2017","unstructured":"Jun S.Y.; Jang I.J.; Yoon S.; Jang K.; Yu K.S.; Cho J.Y.; Seong M.W.; Jung G.M.; Yoon S.J.; Kang S.H.; Pharmacokinetics and tolerance of the phage endolysin-based candidate drug SAL200 after a single intravenous administration among healthy volunteers. Antimicrob Agents Chemother  2017,61(6),e02629-16","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=184","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/B978-0-12-818480-6.00011-4","author":"Hariharan S.","year":"2020","unstructured":"Hariharan S.; Keelara S.; Paul V.D.; Sriram B.; Vipra A.A.; Balganesh T.;  Drug discovery targeting drug-resistant bacteria  2020,301-359","journal-title":"Drug discovery targeting drug-resistant bacteria"},{"key":"ref=185","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1093\/ofid\/ofw172.1533","volume":"3","author":"Rupp M.E.","year":"2016","unstructured":"Rupp M.E.; Stecher M.; Mckinnon J.; Jung N.; Huynh T.; Pharmacokinetics of a novel monoclonal antibody targeting Staphylococcal Protein A in patients hospitalized with S. aureus bacteremia. Open Forum Infect Dis  2016,3(1)(Suppl. 1),1985","journal-title":"Open Forum Infect Dis"},{"key":"ref=186","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1007\/s00134-018-5229-2","volume":"44","author":"Fran\u00e7ois B.","year":"2018","unstructured":"Fran\u00e7ois B.; Mercier E.; Gonzalez C.; Asehnoune K.; Nseir S.; Fiancette M.; Desachy A.; Plantef\u00e8ve G.; Meziani F.; de Lame P.A.; Laterre P.F.; Safety and tolerability of a single administration of AR-301, a human monoclonal antibody, in ICU patients with severe pneumonia caused by Staphylococcus aureus: First-in-human trial. Intensive Care Med  2018,44(11),1787-1796","journal-title":"Intensive Care Med"},{"key":"ref=187","first-page":"1020","volume":"61","author":"Yu X-Q.","year":"2016","unstructured":"Yu X-Q.; Robbie G.J.; Wu Y.; Esser M.T.; Jensen K.; Schwartz H.I.; Bellamy T.; Hernandez-Illas M.; Jafri H.S.; Safety, tolerability, and pharmacokinetics of MEDI4893, an investigational, extended-half-life, anti-Staphylococcus aureus alpha-toxin human monoclonal antibody, in healthy adults. Antimicrob Agents Chemother  2016,61(1),1020-1036","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=188","doi-asserted-by":"publisher","first-page":"2200214","DOI":"10.1002\/ardp.202200214","volume":"355","author":"Reddy D.S.","year":"2022","unstructured":"Reddy D.S.; Sinha A.; Kumar A.; Saini V.K.; Drug re-engineering and repurposing: A significant and rapid approach to tuberculosis drug discovery. Arch Pharm (Weinheim)  2022,355(11),2200214","journal-title":"Arch Pharm (Weinheim)"},{"key":"ref=189","doi-asserted-by":"publisher","first-page":"3952","DOI":"10.1128\/JCM.01643-09","volume":"47","author":"Bae I.G.","year":"2009","unstructured":"Bae I.G.; Tonthat G.T.; Stryjewski M.E.; Rude T.H.; Reilly L.F.; Barriere S.L.; Genter F.C.; Corey G.R.; Fowler V.G.; Presence of genes encoding the panton-valentine leukocidin exotoxin is not the primary determinant of outcome in patients with complicated skin and skin structure infections due to methicillin-resistant Staphylococcus aureus: Results of a multinational trial. J Clin Microbiol  2009,47(12),3952-3957","journal-title":"J Clin Microbiol"},{"key":"ref=190","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1021\/acs.chemrestox.0c00524","volume":"34","author":"Wang W.","year":"2021","unstructured":"Wang W.; Voss K.M.; Liu J.; Gordeev M.F.; Nonclinical evaluation of antibacterial oxazolidinones Contezolid and Contezolid Acefosamil with low serotonergic neurotoxicity. Chem Res Toxicol  2021,34(5),1348-1354","journal-title":"Chem Res Toxicol"},{"key":"ref=191","doi-asserted-by":"publisher","first-page":"e02158-19","DOI":"10.1128\/AAC.02158-19","volume":"64","author":"Wu J.","year":"2020","unstructured":"Wu J.; Cao G.; Wu H.; Chen Y.; Guo B.; Wu X.; Yu J.; Ni K.; Qian J.; Wang L.; Wu J.; Wang Y.; Yuan H.; Zhang J.; Xi Y.; Evaluation of the effect of Contezolid (MRX-I) on the corrected QT interval in a randomized, double-blind, placebo-and positive-controlled crossover study in healthy Chinese volunteers. Antimicrob Agents Chemother  2020,64(6),e02158-19","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=192","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jpba.2017.01.041","volume":"139","author":"Michalska K.","year":"2017","unstructured":"Michalska K.; Gruba E.; Bocian W.; Cielecka-Piontek J.; Enantioselective recognition of radezolid by cyclodextrin modified capillary electrokinetic chromatography and electronic circular dichroism. J Pharm Biomed Anal  2017,139,98-108","journal-title":"J Pharm Biomed Anal"},{"key":"ref=193","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4103\/2229-516X.112229","volume":"3","author":"Kaur M.","year":"2013","unstructured":"Kaur M.; Rai J.; Randhawa G.K.; Recent advances in antibacterial drugs. Int J Appl Basic Med Res  2013,3(1),3-10","journal-title":"Int J Appl Basic Med Res"},{"key":"ref=194","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1177\/0009922807307186","volume":"47","author":"Silverberg N.","year":"2008","unstructured":"Silverberg N.; Block S.; Uncomplicated skin and skin structure infections in children: Diagnosis and current treatment options in the United States. Clin Pediatr (Phila)  2008,47(3),211-219","journal-title":"Clin Pediatr (Phila)"},{"key":"ref=195","doi-asserted-by":"publisher","first-page":"39004","DOI":"10.1038\/srep39004","volume":"6","author":"Eyal Z.","year":"2016","unstructured":"Eyal Z.; Matzov D.; Krupkin M.; Paukner S.; Riedl R.; Rozenberg H.; Zimmerman E.; Bashan A.; Yonath A.; A novel pleuromutilin antibacterial compound, its binding mode and selectivity mechanism. Sci Rep  2016,6(1),39004","journal-title":"Sci Rep"},{"key":"ref=196","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1039\/C8NP00042E","volume":"36","author":"Goethe O.","year":"2019","unstructured":"Goethe O.; Heuer A.; Ma X.; Wang Z.; Herzon S.B.; Antibacterial properties and clinical potential of pleuromutilins. Nat Prod Rep  2019,36(1),220-247","journal-title":"Nat Prod Rep"},{"key":"ref=197","doi-asserted-by":"publisher","first-page":"996","DOI":"10.3390\/molecules22060996","volume":"22","author":"Yi Y.","year":"2017","unstructured":"Yi Y.; Fu Y.; Dong P.; Qin W.; Liu Y.; Liang J.; Shang R.; Synthesis and biological activity evaluation of novel heterocyclic pleuromutilin derivatives. Molecules  2017,22(6),996","journal-title":"Molecules"},{"key":"ref=198","doi-asserted-by":"publisher","first-page":"126969","DOI":"10.1016\/j.bmcl.2020.126969","volume":"30","author":"Li Y.G.","year":"2020","unstructured":"Li Y.G.; Wang J.X.; Zhang G.N.; Zhu M.; You X.F.; Wang Y.C.; Zhang F.; Design, synthesis, and biological activity evaluation of a series of pleuromutilin derivatives with novel C14 side chains. Bioorg Med Chem Lett  2020,30(7),126969","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=199","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1002\/phar.2166","volume":"38","author":"Veve M.P.","year":"2018","unstructured":"Veve M.P.; Wagner J.L.; Lefamulin: Review of a promising novel pleuromutilin antibiotic. Pharmacotherapy  2018,38(9),935-946","journal-title":"Pharmacotherapy"},{"key":"ref=200","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s11908-020-00732-z","volume":"22","author":"Mercuro N.J.","year":"2020","unstructured":"Mercuro N.J.; Veve M.P.; Clinical utility of Lefamulin: If not now, when? Curr Infect Dis Rep  2020,22(9),25","journal-title":"Curr Infect Dis Rep"},{"key":"ref=201","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s40265-020-01443-4","volume":"81","author":"Zhanel G.G.","year":"2021","unstructured":"Zhanel G.G.; Deng C.; Zelenitsky S.; Lawrence C.K.; Adam H.J.; Golden A.; Berry L.; Schweizer F.; Zhanel M.A.; Irfan N.; Bay D.; Lagac\u00e9-Wiens P.; Walkty A.; Mandell L.; Lynch J.P.; Karlowsky J.A.; Lefamulin: A novel oral and intravenous pleuromutilin for the treatment of community-acquired bacterial pneumonia. Drugs  2021,81(2),233-256","journal-title":"Drugs"},{"key":"ref=202","doi-asserted-by":"publisher","first-page":"386","DOI":"10.3390\/microorganisms7100386","volume":"7","author":"Koulenti D.","year":"2019","unstructured":"Koulenti D.; Xu E.; Yin Sum Mok I.; Song A.; Karageorgopoulos D.E.; Armaganidis A.; Lipman J.; Tsiodras S.; Novel antibiotics for multidrug-resistant gram-positive microorganisms. Microorganisms  2019,7(10),386-390","journal-title":"Microorganisms"},{"key":"ref=203","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1345\/aph.1L016","volume":"42","author":"Anderson S.D.","year":"2008","unstructured":"Anderson S.D.; Gums J.G.; Ceftobiprole: An extended-spectrum anti-methicillin-resistant Staphylococcus aureus cephalosporin. Ann Pharmacother  2008,42(6),806-816","journal-title":"Ann Pharmacother"},{"key":"ref=204","doi-asserted-by":"publisher","first-page":"245","DOI":"10.2165\/00128071-200809040-00004","volume":"9","author":"Zhanel G.G.","year":"2008","unstructured":"Zhanel G.G.; Lam A.; Schweizer F.; Thomson K.; Walkty A.; Rubinstein E.; Gin A.S.; Hoban D.J.; Noreddin A.M.; Karlowsky J.A.; Ceftobiprole. A review of a broad spectrum and anti-MRSA cephalosporin.  Am J Clin Dermatol  2008,9(4),245-254","journal-title":"Am J Clin Dermatol"},{"key":"ref=205","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1128\/AAC.00551-07","volume":"52","author":"Noel G.J.","year":"2007","unstructured":"Noel G.J.; Strauss R.S.; Amsler K.; Heep M.; Pypstra R.; Solomkin J.S.; Treatment of complicated skin and skin structure infections caused by gram-positive bacteria with Ceftobiprole: Results of a double-blind, randomized trial. Antimicrob Agents Chemother  2007,52,37-44","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=206","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1086\/526527","volume":"46","author":"Noel G.J.","year":"2008","unstructured":"Noel G.J.; Bush K.; Bagchi P.; Ianus J.; Strauss R.S.; A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis  2008,46(5),647-655","journal-title":"Clin Infect Dis"},{"key":"ref=207","doi-asserted-by":"publisher","first-page":"e02367-19","DOI":"10.1128\/AAC.02367-19","volume":"64","author":"Bhavnani S.M.","year":"2020","unstructured":"Bhavnani S.M.; Hammel J.P.; Lakota E.A.; Safir M.C.; VanScoy B.D.; Nagira Y.; Rubino C.M.; Sato N.; Koresawa T.; Kondo K.; Ambrose P.G.; Pharmacokinetic-pharmacodynamic target attainment analyses to support dose selection for ME1100, an Arbekacin inhalation solution. Antimicrob Agents Chemother  2020,64(10),e02367-19","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=208","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1080\/00498254.2020.1756007","volume":"50","author":"Chavan R.","year":"2020","unstructured":"Chavan R.; Zope V.; Chavan N.; Shaikh J.; Patil K.; Yeole R.; Bhagwat S.; Patel M.; Assessment of in vitro inhibitory effects of novel anti MRSA benzoquinolizine fluoroquinolone WCK 771 (levonadifloxacin) and its metabolite on human liver cytochrome P450 enzymes. Xenobiotica  2020,50(10),1149-1157","journal-title":"Xenobiotica"},{"key":"ref=209","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/cts.12594","volume":"12","author":"Mason J.W.","year":"2019","unstructured":"Mason J.W.; Chugh R.; Patel A.; Gutte R.; Bhatia A.; Electrocardiographic effects of a supratherapeutic dose of WCK 2349, a benzoquinolizine fluoroquinolone. Clin Transl Sci  2019,12(1),47-52","journal-title":"Clin Transl Sci"},{"key":"ref=210","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jmii.2017.07.011","volume":"52","author":"Yuan J.","year":"2019","unstructured":"Yuan J.; Mo B.; Ma Z.; Lv Y.; Cheng S.L.; Yang Y.; Tong Z.; Wu R.; Sun S.; Cao Z.; Wu J.; Zhu D.; Chang L.; Zhang Y.; Zhao L.; Wang X.; Wang X.; Wang D.; Li X.; Peng Y.; Liang Y.; Liu H.; Xiao Z.; Lv X.; Wu S.; Dai Y.; Huang Y.; Hu Z.; Qiu C.; Li X.; Zhang S.; Li W.; Liu S.; Shi Y.; Xiong C.; Kuang J.; Xiu Q.; Cui S.; Li J.; Lin Q.; Huang W.; Wan Y.; Qimanguli ; Shen C.; Xiao Y.; Wu X.; Chuang Y.C.; Perng W.C.; Tsao S-M.; Hsu J-Y.; Wang C-C.; Wang J-H.; Yeh P-F.; Lin H-H.; Kuo P.H.; Lin M-S.; Su W-J.; Safety and efficacy of oral nemonoxacin versus levofloxacin in treatment of community-acquired pneumonia: A phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority trial. J Microbiol Immunol Infect  2019,52(1),35-44","journal-title":"J Microbiol Immunol Infect"},{"key":"ref=211","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.clinthera.2019.04.025","volume":"41","author":"Wu J.","year":"2019","unstructured":"Wu J.; Wu H.; Wang Y.; Chen Y.; Guo B.; Cao G.; Wu X.; Yu J.; Wu J.; Zhu D.; Guo Y.; Yuan H.; Hu F.; Zhang J.; Tolerability and pharmacokinetics of Contezolid at therapeutic and supratherapeutic doses in healthy Chinese subjects, and assessment of Contezolid dosing regimens based on pharmacokinetic\/pharmacodynamic analysis. Clin Ther  2019,41(6),1164-1174.e4","journal-title":"Clin Ther"},{"key":"ref=212","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1517\/14740338.2016.1142528","volume":"15","author":"Bassetti M.","year":"2016","unstructured":"Bassetti M.; Righi E.; Safety profiles of old and new antimicrobials for the treatment of MRSA infections. Expert Opin Drug Saf  2016,15(4),467-481","journal-title":"Expert Opin Drug Saf"},{"key":"ref=213","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1093\/cid\/ciz090","volume":"69","author":"Goldberg L.","year":"2019","unstructured":"Goldberg L.; Das A.; Efficacy and safety of iv-to-oral lefamulin, a pleuromutilin antibiotic, for treatment of communityacquired bacterial pneumonia: The phase 3 LEAP 1 Trial. Clin Infect Dis  2019,69,1856-1867","journal-title":"Clin Infect Dis"},{"key":"ref=214","doi-asserted-by":"publisher","first-page":"e1507","DOI":"10.1093\/cid\/ciaa974","volume":"73","author":"Overcash J.S.","year":"2021","unstructured":"Overcash J.S.; Kim C.; Keech R.; Gumenchuk I.; Ninov B.; Gonzalez-Rojas Y.; Waters M.; Simeonov S.; Engelhardt M.; Saulay M.; Ionescu D.; Smart J.I.; Jones M.E.; Hamed K.A.; Ceftobiprole compared with Vancomycin plus Aztreonam in the treatment of acute bacterial skin and skin structure infections: Results of a Phase 3, randomized, double-blind trial (TARGET). Clin Infect Dis  2021,73(7),e1507-e1517","journal-title":"Clin Infect Dis"},{"key":"ref=215","doi-asserted-by":"publisher","first-page":"15987","DOI":"10.1074\/jbc.M113.532804","volume":"289","author":"Schiebel J.","year":"2014","unstructured":"Schiebel J.; Chang A.; Shah S.; Lu Y.; Liu L.; Pan P.; Hirschbeck M.W.; Tareilus M.; Eltschkner S.; Yu W.; Cummings J.E.; Knudson S.E.; Bommineni G.R.; Walker S.G.; Slayden R.A.; Sotriffer C.A.; Tonge P.J.; Kisker C.; Rational design of broad spectrum antibacterial activity based on a clinically relevant enoyl-acyl carrier protein (ACP) reductase inhibitor. J Biol Chem  2014,289(23),15987-16005","journal-title":"J Biol Chem"},{"key":"ref=216","doi-asserted-by":"publisher","first-page":"e00250-20","DOI":"10.1128\/AAC.00250-20","volume":"64","author":"Wittke F.","year":"2020","unstructured":"Wittke F.; Vincent C.; Chen J.; Heller B.; Kabler H.; Overcash J.S.; Leylavergne F.; Dieppois G.; Afabicin, a first-in-class anti-staphylococcal antibiotic, in the treatment of acute bacterial skin and skin structure infections: Clinical non-inferiority to vancomycin\/linezolid. Antimicrob Agents Chemother  2020,64(10),e00250-20","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=217","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jgar.2019.09.017","volume":"21","author":"Yendewa G.A.","year":"2020","unstructured":"Yendewa G.A.; Griffiss J.M.; Jacobs M.R.; Fulton S.A.; O\u2019Riordan M.A.; Gray W.A.; Proskin H.M.; Winkle P.; Salata R.A.; A two-part phase 1 study to establish and compare the safety and local tolerability of two nasal formulations of XF-73 for decolonisation of Staphylococcus aureus: A previously investigated 0.5 mg\/g viscosified gel formulation versus a modified formulation. J Glob Antimicrob Resist  2020,21,171-180","journal-title":"J Glob Antimicrob Resist"},{"key":"ref=218","doi-asserted-by":"publisher","first-page":"2834","DOI":"10.1128\/AAC.01383-08","volume":"53","author":"Krievins D.","year":"2009","unstructured":"Krievins D.; Brandt R.; Hawser S.; Hadvary P.; Islam K.; Multicenter, randomized study of the efficacy and safety of intravenous iclaprim in complicated skin and skin structure infections. Antimicrob Agents Chemother  2009,53(7),2834-2840","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=219","year":"2022","unstructured":"Our Pipeline. TAXIS Available From:  https:\/\/www.taxispharma.com\/research development\/our-pipeline\/2022"},{"key":"ref=220","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1093\/ofid\/ofw172.1057","volume":"3","author":"Huynh T.","year":"2016","unstructured":"Huynh T.; Stecher M.; Mckinnon J.; Jung N.; Rupp M.E.; Safety and tolerability of 514G3, a true human anti-protein a monoclonal antibody for the treatment of S. aureus bacteremia. Open Forum Infect Dis  2016,3(1)(Suppl. 1),1354","journal-title":"Open Forum Infect Dis"},{"key":"ref=221","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ijmm.2013.08.009","volume":"304","author":"Schneider T.","year":"2014","unstructured":"Schneider T.; M\u00fcller A.; Miess H.; Gross H.; Cyclic lipopeptides as antibacterial agents \u2013 Potent antibiotic activity mediated by intriguing mode of actions. Int J Med Microbiol  2014,304(1),37-43","journal-title":"Int J Med Microbiol"},{"key":"ref=222","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1111\/1751-7915.13484","volume":"12","author":"Chen X.","year":"2019","unstructured":"Chen X.; Li S.; Yu L.; Miller A.; Du L.; Systematic optimization for production of the anti-  antibiotics  -8294A in an engineered strain of Lysobacter enzymogenes. Microb Biotechnol  2019,12(6),1430-1440","journal-title":"Microb Biotechnol"},{"key":"ref=223","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/ja.2011.44","volume":"64","author":"Butler M.S.","year":"2011","unstructured":"Butler M.S.; Cooper M.A.; Antibiotics in the clinical pipeline in 2011. J Antibiot (Tokyo)  2011,64(6),413-425","journal-title":"J Antibiot (Tokyo)"},{"key":"ref=224","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.coph.2012.07.004","volume":"12","author":"Moir D.T.","year":"2012","unstructured":"Moir D.T.; Opperman T.J.; Butler M.M.; Bowlin T.L.; New classes of antibiotics. Curr Opin Pharmacol  2012,12(5),535-544","journal-title":"Curr Opin Pharmacol"},{"key":"ref=225","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.ijantimicag.2010.02.008","volume":"35","author":"Farrell D.J.","year":"2010","unstructured":"Farrell D.J.; Robbins M.; Rhys-Williams W.; Love W.G.; In vitro activity of XF-73, a novel antibacterial agent, against antibiotic-sensitive and -resistant gram-positive and gram-negative bacterial species. Int J Antimicrob Agents  2010,35(6),531-536","journal-title":"Int J Antimicrob Agents"},{"key":"ref=226","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1080\/14787210.2019.1604220","volume":"17","author":"Sakr A.","year":"2019","unstructured":"Sakr A.; Br\u00e9geon F.; Rolain J.M.; Blin O.; Staphylococcus aureus nasal decolonization strategies: A review. Expert Rev Anti Infect Ther  2019,17(5),327-340","journal-title":"Expert Rev Anti Infect Ther"},{"key":"ref=227","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1093\/jac\/dkm409","volume":"60","author":"Laue H.","year":"2007","unstructured":"Laue H.; Weiss L.; Bernardi A.; Hawser S.; Lociuro S.; Islam K.; In vitro activity of the novel diaminopyrimidine, iclaprim, in combination with folate inhibitors and other antimicrobials with different mechanisms of action. J Antimicrob Chemother  2007,60(6),1391-1394","journal-title":"J Antimicrob Chemother"},{"key":"ref=228","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1517\/13543784.16.9.1441","volume":"16","author":"Kohlhoff S.A.","year":"2007","unstructured":"Kohlhoff S.A.; Sharma R.; Iclaprim. Expert Opin Investig Drugs  2007,16(9),1441-1448","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=229","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1345\/aph.1L167","volume":"43","author":"Sincak C.A.","year":"2009","unstructured":"Sincak C.A.; Schmidt J.M.; Iclaprim, a novel diaminopyrimidine for the treatment of resistant gram-positive infections. Ann Pharmacother  2009,43(6),1107-1114","journal-title":"Ann Pharmacother"},{"key":"ref=230","doi-asserted-by":"publisher","first-page":"6645","DOI":"10.1021\/acs.jmedchem.6b00485","volume":"59","author":"Ma Z.","year":"2016","unstructured":"Ma Z.; Lynch A.S.; Development of a dual-acting antibacterial agent (TNP-2092) for the treatment of persistent bacterial infections. J Med Chem  2016,59(14),6645-6657","journal-title":"J Med Chem"},{"key":"ref=231","first-page":"1","volume":"28","author":"Nazli A.","year":"2021","unstructured":"Nazli A.; He D.; Xu H.; Wang Z-P.; He Y.; A comparative insight on the newly emerging rifamycins: Rifametane, Rifalazil, TNP-2092 and TNP-2198. Curr Med Chem  2021,28,1-30","journal-title":"Curr Med Chem"},{"key":"ref=232","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1093\/jac\/dkm236","volume":"60","author":"Park H.S.","year":"2007","unstructured":"Park H.S.; Yoon Y.M.; Jung S.J.; Kim C.M.; Kim J.M.; Kwak J.H.; Antistaphylococcal activities of CG400549, a new bacterial enoyl-acyl carrier protein reductase (FabI) inhibitor. J Antimicrob Chemother  2007,60(3),568-574","journal-title":"J Antimicrob Chemother"},{"key":"ref=233","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0732-8893(99)00104-2","volume":"36","author":"You I.","year":"2000","unstructured":"You I.; Kariyama R.; Zervos M.J.; Kumon H.; Chow J.W.; In-vitro activity of arbekacin alone and in combination with vancomycin against gentamicin- and methicillin-resistant Staphylococcus aureus. Diagn Microbiol Infect Dis  2000,36(1),37-41","journal-title":"Diagn Microbiol Infect Dis"},{"key":"ref=234","doi-asserted-by":"publisher","first-page":"4754","DOI":"10.1128\/AAC.48.12.4754-4761.2004","volume":"48","author":"Patel M.V.","year":"2004","unstructured":"Patel M.V.; De Souza N.J.; Gupte S.V.; Jafri M.A.; Bhagwat S.S.; Chugh Y.; Khorakiwala H.F.; Jacobs M.R.; Appelbaum P.C.; Antistaphylococcal activity of WCK 771, a tricyclic fluoroquinolone, in animal infection models. Antimicrob Agents Chemother  2004,48(12),4754-4761","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=235","doi-asserted-by":"publisher","first-page":"3631","DOI":"10.1128\/AAC.00162-11","volume":"55","author":"Farrell D.J.","year":"2011","unstructured":"Farrell D.J.; Liverman L.C.; Biedenbach D.J.; Jones R.N.; JNJ-Q2, a new fluoroquinolone with potent In vitro activity against Staphylococcus aureus, including methicillin- and fluoroquinolone-resistant strains. Antimicrob Agents Chemother  2011,55(7),3631-3634","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=236","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1128\/AAC.01285-10","volume":"55","author":"Farrell D.J.","year":"2011","unstructured":"Farrell D.J.; Robbins M.; Rhys-Williams W.; Love W.G.; Investigation of the potential for mutational resistance to XF-73, retapamulin, mupirocin, fusidic acid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus isolates during a 55-passage study. Antimicrob Agents Chemother  2011,55(3),1177-1181","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=237","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1093\/jac\/dks307","volume":"67","author":"Remy J.M.","year":"2012","unstructured":"Remy J.M.; Tow-Keogh C.A.; McConnell T.S.; Dalton J.M.; DeVito J.A.; Activity of delafloxacin against methicillin-resistant Staphylococcus aureus: Resistance selection and characterization. J Antimicrob Chemother  2012,67(12),2814-2820","journal-title":"J Antimicrob Chemother"},{"key":"ref=238","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1080\/14787210.2018.1536545","volume":"16","author":"Noviello S.","year":"2018","unstructured":"Noviello S.; Huang D.B.; Corey G.R.; Iclaprim: A differentiated option for the treatment of skin and skin structure infections. Expert Rev Anti Infect Ther  2018,16(11),793-803","journal-title":"Expert Rev Anti Infect Ther"},{"key":"ref=239","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1007\/s11274-014-1720-2","volume":"30","author":"Li Z.","year":"2014","unstructured":"Li Z.; Liu Y.; Wang R.; Li A.; Antibacterial activities of nemonoxacin against clinical isolates of Staphylococcus aureus: An in vitro comparison with three fluoroquinolones. World J Microbiol Biotechnol  2014,30(11),2927-2932","journal-title":"World J Microbiol Biotechnol"},{"key":"ref=240","doi-asserted-by":"publisher","first-page":"e00468-17","DOI":"10.1128\/AAC.00468-17","volume":"61","author":"Flamm R.K.","year":"2017","unstructured":"Flamm R.K.; Farrell D.J.; Rhomberg P.R.; Scangarella-Oman N.E.; Sader H.S.; Gepotidacin (GSK2140944) In vitro activity against gram-positive and gram-negative bacteria.  Antimicrob Agents Chemother  2017,61(7),e00468-17","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=241","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1128\/AAC.01672-10","volume":"55","author":"McGhee P.","year":"2011","unstructured":"McGhee P.; Clark C.; Credito K.; Beachel L.; Pankuch G.A.; Appelbaum P.C.; Kosowska-Shick K.; In vitro activity of fusidic acid (CEM-102, sodium fusidate) against Staphylococcus aureus isolates from cystic fibrosis patients and its effect on the activities of tobramycin and amikacin against Pseudomonas aeruginosa and Burkholderia cepacia. Antimicrob Agents Chemother  2011,55(5),2417-2419","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=242","author":"Sader H.","unstructured":"Sader H.; Rhomberg P.; Duncan L.; Flamm R.;   In vitro activity and potency of the novel oxazolidinone MRX-I tested against contemporary clinical isolates of Gram-positive bacteria. American Society for Microbiology (ASM Microbe), 2017."},{"key":"ref=243","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1128\/AAC.01383-07","volume":"52","author":"Lawrence L.","year":"2008","unstructured":"Lawrence L.; Danese P.; DeVito J.; Franceschi F.; Sutcliffe J.; In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. Antimicrob Agents Chemother  2008,52(5),1653-1662","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=244","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1128\/AAC.02566-12","volume":"57","author":"O\u2019Dwyer K.","year":"2013","unstructured":"O\u2019Dwyer K.; Hackel M.; Hightower S.; Hoban D.; Bouchillon S.; Qin D.; Aubart K.; Zalacain M.; Butler D.; Comparative analysis of the antibacterial activity of a novel peptide deformylase inhibitor, GSK1322322. Antimicrob Agents Chemother  2013,57(5),2333-2342","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=245","doi-asserted-by":"publisher","first-page":"15693","DOI":"10.1021\/acs.jmedchem.0c01328","volume":"63","author":"Heidtmann C.V.","year":"2020","unstructured":"Heidtmann C.V.; Voukia F.; Hansen L.N.; S\u00f8rensen S.H.; Urlund B.; Nielsen S.; Pedersen M.; Kelawi N.; Andersen B.N.; Pedersen M.; Reinholdt P.; Kongsted J.; Nielsen C.U.; Klitgaard J.K.; Nielsen P.; Discovery of a potent adenine\u2013benzyltriazolo\u2013pleuromutilin conjugate with pronounced antibacterial activity against MRSA. J Med Chem  2020,63(24),15693-15708","journal-title":"J Med Chem"},{"key":"ref=246","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1128\/AAC.05789-11","volume":"56","author":"Sader H.S.","year":"2012","unstructured":"Sader H.S.; Biedenbach D.J.; Paukner S.; Ivezic-Schoenfeld Z.; Jones R.N.; Antimicrobial activity of the investigational pleuromutilin compound BC-3781 tested against Gram-positive organisms commonly associated with acute bacterial skin and skin structure infections. Antimicrob Agents Chemother  2012,56(3),1619-1623","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=247","doi-asserted-by":"publisher","first-page":"7280","DOI":"10.1128\/AAC.01118-16","volume":"60","author":"Nair S.","year":"2016","unstructured":"Nair S.; Desai S.; Poonacha N.; Vipra A.; Sharma U.; Antibiofilm activity and synergistic inhibition of Staphylococcus aureus biofilms by bactericidal protein P128 in combination with antibiotics. Antimicrob Agents Chemother  2016,60(12),7280-7289","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=248","doi-asserted-by":"publisher","first-page":"35442","DOI":"10.1038\/srep35442","volume":"6","author":"Iqbal Z.","year":"2016","unstructured":"Iqbal Z.; Seleem M.N.; Hussain H.I.; Huang L.; Hao H.; Yuan Z.; Comparative virulence studies and transcriptome analysis of Staphylococcus aureus strains isolated from animals. Sci Rep  2016,6(1),35442","journal-title":"Sci Rep"},{"key":"ref=249","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1097\/QCO.0000000000000708","volume":"34","author":"Giacobbe D.R.","year":"2021","unstructured":"Giacobbe D.R.; Labate L.; Vena A.; Bassetti M.; Potential role of new-generation antibiotics in acute bacterial skin and skin structure infections. Curr Opin Infect Dis  2021,34(2),109-117","journal-title":"Curr Opin Infect Dis"},{"key":"ref=250","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1042\/BCJ20200610","volume":"478","author":"Temme J.S.","year":"2021","unstructured":"Temme J.S.; Butler D.L.; Gildersleeve J.C.; Anti-glycan antibodies: Roles in human disease. Biochem J  2021,478(8),1485-1509","journal-title":"Biochem J"},{"key":"ref=251","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/nature16057","volume":"527","author":"Lehar S.M.","year":"2015","unstructured":"Lehar S.M.; Pillow T.; Xu M.; Staben L.; Kajihara K.K.; Vandlen R.; DePalatis L.; Raab H.; Hazenbos W.L.; Hiroshi Morisaki J.; Kim J.; Park S.; Darwish M.; Lee B.C.; Hernandez H.; Loyet K.M.; Lupardus P.; Fong R.; Yan D.; Chalouni C.; Luis E.; Khalfin Y.; Plise E.; Cheong J.; Lyssikatos J.P.; Strandh M.; Koefoed K.; Andersen P.S.; Flygare J.A.; Wah Tan M.; Brown E.J.; Mariathasan S.; Novel antibody-antibiotic conjugate eliminates intracellular S. aureus. Nature  2015,527(7578),323-328","journal-title":"Nature"},{"key":"ref=252","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1038\/nchem.2635","volume":"8","author":"Staben L.R.","year":"2016","unstructured":"Staben L.R.; Koenig S.G.; Lehar S.M.; Vandlen R.; Zhang D.; Chuh J.; Yu S.F.; Ng C.; Guo J.; Liu Y.; Fourie-O\u2019Donohue A.; Go M.; Linghu X.; Segraves N.L.; Wang T.; Chen J.; Wei B.; Phillips G.D.L.; Xu K.; Kozak K.R.; Mariathasan S.; Flygare J.A.; Pillow T.H.; Targeted drug delivery through the traceless release of tertiary and heteroaryl amines from antibody\u2013drug conjugates. Nat Chem  2016,8(12),1112-1119","journal-title":"Nat Chem"},{"key":"ref=253","first-page":"93","volume":"67","author":"Panchal G.","year":"2019","unstructured":"Panchal G.; Pandit R.; Trailokya A.; Sharma A.; Arbekacin-a novel antibiotic for critical infections. J Assoc Physicians India  2019,67(7),93-97","journal-title":"J Assoc Physicians India"},{"key":"ref=254","doi-asserted-by":"publisher","first-page":"3636","DOI":"10.1016\/j.bmcl.2015.06.057","volume":"25","author":"Singh S.B.","year":"2015","unstructured":"Singh S.B.; Kaelin D.E.; Wu J.; Miesel L.; Tan C.M.; Meinke P.T.; Olsen D.B.; Lagrutta A.; Wei C.; Liao Y.; Peng X.; Wang X.; Fukuda H.; Kishii R.; Takei M.; Yajima M.; Shibue T.; Shibata T.; Ohata K.; Nishimura A.; Fukuda Y.; Structure activity relationship of pyridoxazinone substituted RHS analogs of oxabicyclooctane-linked 1,5-naphthyridinyl novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents (Part-6). Bioorg Med Chem Lett  2015,25(17),3636-3643","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=255","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.ejmech.2013.01.048","volume":"63","author":"Shang R.","year":"2013","unstructured":"Shang R.; Liu Y.; Xin Z.; Guo W.; Guo Z.; Hao B.; Jianping L.; Synthesis and antibacterial evaluation of novel pleuromutilin derivatives. Eur J Med Chem  2013,63,231-238","journal-title":"Eur J Med Chem"},{"key":"ref=256","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.2217\/fmb.15.115","volume":"10","author":"Scheeren T.W.L.","year":"2015","unstructured":"Scheeren T.W.L.; Ceftobiprole medocaril in the treatment of hospital-acquired pneumonia. Future Microbiol  2015,10(12),1913-1928","journal-title":"Future Microbiol"},{"key":"ref=257","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1128\/AAC.01562-06","volume":"51","author":"Yum J.H.","year":"2007","unstructured":"Yum J.H.; Kim C.K.; Yong D.; Lee K.; Chong Y.; Kim C.M.; Kim J.M.; Ro S.; Cho J.M.; In vitro activities of CG400549, a novel FabI inhibitor, against recently isolated clinical staphylococcal strains in Korea. Antimicrob Agents Chemother  2007,51(7),2591-2593","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=258","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ejps.2017.08.002","volume":"109","author":"Rautio J.","year":"2017","unstructured":"Rautio J.; K\u00e4rkk\u00e4inen J.; Sloan K.B.; Prodrugs \u2013 Recent approvals and a glimpse of the pipeline. Eur J Pharm Sci  2017,109,146-161","journal-title":"Eur J Pharm Sci"},{"key":"ref=259","doi-asserted-by":"publisher","first-page":"7151","DOI":"10.1128\/AAC.01690-15","volume":"59","author":"Ross J.E.","year":"2015","unstructured":"Ross J.E.; Flamm R.K.; Jones R.N.; Initial broth microdilution quality control guidelines for Debio 1452, a FabI inhibitor antimicrobial agent. Antimicrob Agents Chemother  2015,59(11),7151-7152","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=260","doi-asserted-by":"publisher","first-page":"4217","DOI":"10.1016\/j.bmcl.2003.07.023","volume":"13","author":"Schneider P.","year":"2003","unstructured":"Schneider P.; Hawser S.; Islam K.; Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria. Bioorg Med Chem Lett  2003,13(23),4217-4221","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=261","doi-asserted-by":"publisher","first-page":"659845","DOI":"10.3389\/fchem.2021.659845","volume":"9","author":"Surur A.S.","year":"2021","unstructured":"Surur A.S.; Sun D.; Macrocycle-antibiotic hybrids: A path to clinical candidates. Front Chem  2021,9,659845","journal-title":"Front Chem"},{"key":"ref=262","doi-asserted-by":"publisher","first-page":"617","DOI":"10.3390\/ijms22020617","volume":"22","author":"De Rosa M.","year":"2021","unstructured":"De Rosa M.; Verdino A.; Soriente A.; Marabotti A.; The odd couple (s): An overview of beta-lactam antibiotics bearing more than one pharmacophoric group. Int J Mol Sci  2021,22(2),617-638","journal-title":"Int J Mol Sci"},{"key":"ref=263","unstructured":"Lemaire, S.; Van Bambeke, F.; Tulkens, P.M. Contrasting effect of acidic pH on the batericidal activities of CEM-102 (fusidic acid) vs. linezolid and clindamycin towards Staphylococcus aureus, 49 Interscience conference on antimicrobial agents and chemotherapy (ICAAC), San Francisco, California, Sep 12-15, 2009."},{"key":"ref=264","author":"Marinelli F.","year":"2013","unstructured":"Marinelli F.; Genilloud O.;  Antimicrobials: New and old molecules in the fight against multi-resistant bacteria  2013","journal-title":"Antimicrobials: New and old molecules in the fight against multi-resistant bacteria"},{"key":"ref=265","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1021\/acs.jcim.8b00105","volume":"58","author":"Kaur G.","year":"2018","unstructured":"Kaur G.; Pavadai E.; Wittlin S.; Chibale K.; 3D-QSAR modeling and synthesis of new fusidic acid derivatives as antiplasmodial agents. J Chem Inf Model  2018,58(8),1553-1560","journal-title":"J Chem Inf Model"},{"key":"ref=266","year":"2019","unstructured":"Oral sodium fusidate (CEM-102) versus oral linezolid for the treatment of acute bacterial skin and skin structure infections. Clinicaltrials.gov Available From:  https:\/\/clinicaltrials.gov\/ct2\/show\/NCT025704902019"},{"key":"ref=267","year":"2018","unstructured":"Comparative study of NXL103 versus Linezolid in Adults with Acute Bacterial Skin and Skin Structure Infections (ABSSSI). Clinicaltrials.gov Available From:  https:\/\/clinicaltrials.gov\/ct2\/show\/NCT009491302018"},{"key":"ref=268","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1021\/acs.accounts.0c00894","volume":"54","author":"Cai L.","year":"2021","unstructured":"Cai L.; Seiple I.B.; Li Q.; Modular chemical synthesis of streptogramin and lankacidin antibiotics. Acc Chem Res  2021,54(8),1891-1908","journal-title":"Acc Chem Res"},{"key":"ref=269","year":"2016","unstructured":"Biocidium. Tracxn Available From:  https:\/\/tracxn.com\/d\/companies\/biocidium\/__A1AwtbyuPpFosPFzBrVDoWk6tH1IzPhIJlK_Tt94OiE2016"},{"key":"ref=270","doi-asserted-by":"publisher","first-page":"621","DOI":"10.3390\/antibiotics9090621","volume":"9","author":"Vander Elst N.","year":"2020","unstructured":"Vander Elst N.; Linden S.B.; Lavigne R.; Meyer E.; Briers Y.; Nelson D.C.; Characterization of the bacteriophage-derived endolysins PlySs2 and PlySs9 with in vitro lytic activity against bovine mastitis Streptococcus uberis. Antibiotics (Basel)  2020,9(9),621-635","journal-title":"Antibiotics (Basel)"},{"key":"ref=271","doi-asserted-by":"publisher","first-page":"e02723-20","DOI":"10.1128\/AAC.02723-20","volume":"65","author":"Swift S.M.","year":"2021","unstructured":"Swift S.M.; Sauve K.; Cassino C.; Schuch R.; Exebacase is active in vitro in pulmonary surfactant and is efficacious alone and synergistic with Daptomycin in a mouse model of lethal Staphylococcus aureus lung infection. Antimicrob Agents Chemother  2021,65(9),e02723-20","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=272","first-page":"675","volume":"3","author":"Bamberger D.M.","year":"2007","unstructured":"Bamberger D.M.; Bacteremia and endocarditis due to methicillin-resistant Staphylococcus aureus: The potential role of daptomycin. Ther Clin Risk Manag  2007,3(4),675-684","journal-title":"Ther Clin Risk Manag"},{"key":"ref=273","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2217\/fmb.10.155","volume":"6","author":"Rasmussen R.V.","year":"2011","unstructured":"Rasmussen R.V.; Fowler V.G.; Skov R.; Bruun N.E.; Future challenges and treatment of Staphylococcus aureus bacteremia with emphasis on MRSA. Future Microbiol  2011,6(1),43-56","journal-title":"Future Microbiol"},{"key":"ref=274","unstructured":"Fowler, V.; Das, A.; Lipka, J.; Schuch, R.; Cassino, C. Exebacase (lysin CF-301) improved clinical responder rates in methicillin-resistant Staphylococcus aureus bacteremia and endocarditis compared to standard of care antibiotics alone in a first-in-patient phase 2 study. In European congress of clinical microbiology and infectious diseases,  Amsterdam, Netherland, 2019."},{"key":"ref=275","year":"2021","unstructured":"Safety, efficacy and pharmacokinetics of CF-301 vs. placebo in addition to antibacterial therapy for treatment of S. Aureus Bacteremia. Clinicaltrials.gov Available From:  https:\/\/clinicaltrials.gov\/ct2\/show\/NCT031634462021"},{"key":"ref=276","year":"2022","unstructured":"Expanded access study of exebacase in COVID-19 patients with persistent MRSA bacteremia. Clinicaltrials.gov Available From:  https:\/\/clinicaltrials.gov\/ct2\/show\/NCT045972422022"},{"key":"ref=277","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1080\/17512433.2019.1619454","volume":"12","author":"Rello J.","year":"2019","unstructured":"Rello J.; Parisella F.R.; Perez A.; Alternatives to antibiotics in an era of difficult-to-treat resistance: New insights. Expert Rev Clin Pharmacol  2019,12(7),635-642","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref=278","doi-asserted-by":"publisher","first-page":"115471","DOI":"10.1016\/j.diagmicrobio.2021.115471","volume":"101","author":"Huang D.B.","year":"2021","unstructured":"Huang D.B.; Sader H.S.; Rhomberg P.R.; Gaukel E.; Borroto-Esoda K.; Anti-staphylococcal lysin, LSVT-1701, activity: In vitro susceptibility of Staphylococcus aureus and coagulase-negative staphylococci (CoNS) clinical isolates from around the world collected from 2002 to 2019. Diagn Microbiol Infect Dis  2021,101(3),115471-115477","journal-title":"Diagn Microbiol Infect Dis"},{"key":"ref=279","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.cmi.2017.02.035","volume":"23","author":"Fran\u00e7ois B.","year":"2017","unstructured":"Fran\u00e7ois B.; Barraud O.; Jafri H.S.; Antibody-based therapy to combat Staphylococcus aureus infections. Clin Microbiol Infect  2017,23(4),219-221","journal-title":"Clin Microbiol Infect"},{"key":"ref=280","year":"2017","unstructured":"XBiotech announces top-line results for 514G3 antibody therapy in serious Staphylococcus aureus infections. GlobeNewswire Available From:  https:\/\/www.globenewswire.com\/news-release\/2017\/04\/03\/953500\/0\/en\/XBiotech-Announces-Top-Line-Results-for-514G3-Antibody-Therapy-in-Serious-Staphylococcus-aureus-Infections.html2017"},{"key":"ref=281","year":"2017","unstructured":"A study of the safety and efficacy of 514g3 in subjects hospitalized with bacteremia due to Staphylococcus aureus. Clinicaltrials.gov Available From:  https:\/\/clinicaltrials.gov\/ct2\/show\/NCT023579662017"},{"key":"ref=282","doi-asserted-by":"publisher","first-page":"894","DOI":"10.3201\/eid1206.051141","volume":"12","author":"Hageman J.C.","year":"2006","unstructured":"Hageman J.C.; Uyeki T.M.; Francis J.S.; Jernigan D.B.; Wheeler J.G.; Bridges C.B.; Barenkamp S.J.; Sievert D.M.; Srinivasan A.; Doherty M.C.; McDougal L.K.; Killgore G.E.; Lopatin U.A.; Coffman R.; MacDonald J.K.; McAllister S.K.; Fosheim G.E.; Patel J.B.; McDonald L.C.; Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season. Emerg Infect Dis  2006,12(6),894-899","journal-title":"Emerg Infect Dis"},{"key":"ref=283","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3390\/vaccines9020151","volume":"9","author":"Mayor A.","year":"2021","unstructured":"Mayor A.; Chesnay A.; Desoubeaux G.; Ternant D.; Heuz\u00e9-Vourc\u2019h N.; S\u00e9cher T.; Therapeutic antibodies for the treatment of respiratory tract infections\u2014current overview and perspectives. Vaccines (Basel)  2021,9(2),151-172","journal-title":"Vaccines (Basel)"},{"key":"ref=284","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.drudis.2020.10.011","volume":"26","author":"Vanamala K.","year":"2021","unstructured":"Vanamala K.; Tatiparti K.; Bhise K.; Sau S.; Scheetz M.H.; Rybak M.J.; Andes D.; Iyer A.K.; Novel approaches for the treatment of methicillin-resistant Staphylococcus aureus: Using nanoparticles to overcome multidrug resistance. Drug Discov Today  2021,26(1),31-43","journal-title":"Drug Discov Today"},{"key":"ref=285","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nrmicro821","volume":"2","author":"Hall-Stoodley L.","year":"2004","unstructured":"Hall-Stoodley L.; Costerton J.W.; Stoodley P.; Bacterial biofilms: From the natural environment to infectious diseases. Nat Rev Microbiol  2004,2(2),95-108","journal-title":"Nat Rev Microbiol"},{"key":"ref=286","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.2042-7158.2010.01183.x","volume":"63","author":"Salem A.H.","year":"2010","unstructured":"Salem A.H.; Elkhatib W.F.; Noreddin A.M.; Pharmacodynamic assessment of vancomycin\u2013rifampicin combination against methicillin resistant Staphylococcus Aureus biofilm: A parametric response surface analysis. J Pharm Pharmacol  2010,63(1),73-79","journal-title":"J Pharm Pharmacol"},{"key":"ref=287","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.drudis.2012.03.012","volume":"17","author":"Dube D.","year":"2012","unstructured":"Dube D.; Agrawal G.P.; Vyas S.P.; Tuberculosis: From molecular pathogenesis to effective drug carrier design. Drug Discov Today  2012,17(13-14),760-773","journal-title":"Drug Discov Today"},{"key":"ref=288","doi-asserted-by":"publisher","first-page":"4180","DOI":"10.1021\/acs.nanolett.8b01000","volume":"18","author":"Li J.","year":"2018","unstructured":"Li J.; Zhang K.; Ruan L.; Chin S.F.; Wickramasinghe N.; Liu H.; Ravikumar V.; Ren J.; Duan H.; Yang L.; Chan-Park M.B.; Block copolymer nanoparticles remove biofilms of drug-resistant gram-positive bacteria by nanoscale bacterial debridement. Nano Lett  2018,18(7),4180-4187","journal-title":"Nano Lett"},{"key":"ref=289","doi-asserted-by":"publisher","first-page":"e1007087","DOI":"10.1371\/journal.pcbi.1007087","volume":"15","author":"Mikkaichi T.","year":"2019","unstructured":"Mikkaichi T.; Yeaman M.R.; Hoffmann A.; Group M.S.I.; Identifying determinants of persistent MRSA bacteremia using mathematical modeling. PLOS Comput Biol  2019,15(7),e1007087","journal-title":"PLOS Comput Biol"},{"key":"ref=290","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.3389\/fmicb.2017.01917","volume":"8","author":"Grassi L.","year":"2017","unstructured":"Grassi L.; Di Luca M.; Maisetta G.; Rinaldi A.C.; Esin S.; Trampuz A.; Batoni G.; Generation of persister cells of Pseudomonas aeruginosa and Staphylococcus aureus by chemical treatment and evaluation of their susceptibility to membrane-targeting agents. Front Microbiol  2017,8,1917-1929","journal-title":"Front Microbiol"},{"key":"ref=291","doi-asserted-by":"publisher","first-page":"779","DOI":"10.4155\/fmc-2017-0199","volume":"10","author":"Kim W.","year":"2018","unstructured":"Kim W.; Hendricks G.L.; Tori K.; Fuchs B.B.; Mylonakis E.; Strategies against methicillin-resistant Staphylococcus aureus persisters. Future Med Chem  2018,10(7),779-794","journal-title":"Future Med Chem"},{"key":"ref=292","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3390\/antibiotics9020065","volume":"9","author":"Pacios O.","year":"2020","unstructured":"Pacios O.; Blasco L.; Bleriot I.; Fernandez-Garcia L.; Gonz\u00e1lez Bardanca M.; Ambroa A.; L\u00f3pez M.; Bou G.; Tom\u00e1s M.; Strategies to combat multidrug-resistant and persistent infectious diseases. Antibiotics (Basel)  2020,9(2),65-68","journal-title":"Antibiotics (Basel)"},{"key":"ref=293","doi-asserted-by":"publisher","first-page":"e42","DOI":"10.1086\/506568","volume":"43","author":"Hageman J.C.","year":"2006","unstructured":"Hageman J.C.; Liedtke L.A.; Sunenshine R.H.; Strausbaugh L.J.; McDonald L.C.; Tenover F.C.; Management of persistent bacteremia caused by methicillin-resistant Staphylococcus aureus: A survey of infectious diseases consultants. Clin Infect Dis  2006,43(5),e42-e45","journal-title":"Clin Infect Dis"},{"key":"ref=294","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/jac\/dkr437","volume":"67","author":"Moellering R.C.","year":"2012","unstructured":"Moellering R.C.; MRSA: The first half century. J Antimicrob Chemother  2012,67(1),4-11","journal-title":"J Antimicrob Chemother"},{"key":"ref=295","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/ja.2013.86","volume":"66","author":"Butler M.S.","year":"2013","unstructured":"Butler M.S.; Blaskovich M.A.; Cooper M.A.; Antibiotics in the clinical pipeline in 2013. J Antibiot (Tokyo)  2013,66(10),571-591","journal-title":"J Antibiot (Tokyo)"},{"key":"ref=296","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/S0924-8579(07)00158-6","volume":"29","author":"Livermore D.M.","year":"2007","unstructured":"Livermore D.M.; Introduction: The challenge of multiresistance. Int J Antimicrob Agents  2007,29(Suppl. 3),S1-S7","journal-title":"Int J Antimicrob Agents"},{"key":"ref=297","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1517\/14728222.9.2.253","volume":"9","author":"Barrett J.F.","year":"2005","unstructured":"Barrett J.F.; MRSA \u2013 what is it, and how do we deal with the problem? Expert Opin Ther Targets  2005,9(2),253-265","journal-title":"Expert Opin Ther Targets"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0109298673249381231130111352","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/225859\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0109298673249381231130111352","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T20:14:43Z","timestamp":1724962483000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/225859\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":297,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0109298673249381231130111352","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-02-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-10","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}